Supplementary material

Title: Recurrent tuberculosis: a systematic review and meta-analysis of the incidence rates and the proportions of relapse and reinfection

Vega V (1), Rodríguez S (1), Van der Stuyft P (2), Seas C (1,3), Otero L (1,3).

Vega V, *et al. Thorax* 2021; 76:494–502. doi: 10.1136/thoraxjnl-2020-215449

Appendix 1 Search strategy

Search strategy PUBMED

((((((((((("tuberculosis"[MeSH Terms]) OR "tuberculosis"[Title/Abstract])) AND ((((("recurrence"[MeSH Terms]) OR recurren*[Tite/Abstract])) OR ((((reinfection*[Title/Abstract]) OR relapse*[Title/Abstract])) OR "reactivation*"[Title/Abstract])))))) NOT (((""addresses""[Publication Type] OR ""autobiography""[Publication Type] OR ""bibliography""[Publication Type] OR ""book illustrations""[Publication Type] OR ""case reports""[Publication Type] OR ""comment""[Publication Type] OR ""dictionary""[Publication Type] OR ""directory""[Publication Type] OR ""editorial""[Publication Type] OR ""electronic supplementary materials""[Publication Type] OR ""ephemera""[Publication Type] OR ""expression of concern""[Publication Type] OR ""festschrift""[Publication Type] OR ""government publications""[Publication Type] OR ""guideline""[Publication Type] OR ""interactive tutorial""[Publication Type] OR ""interview""[Publication Type] OR ""lectures""[Publication Type] OR ""legal cases""[Publication Type] OR ""legislation""[Publication Type] OR ""letter""[Publication Type] OR ""news""[Publication Type] OR ""newspaper article""[Publication Type] OR ""patient education handout""[Publication Type] OR ""periodical index""[Publication Type] OR ""personal narratives""[Publication Type] OR ""pictorial works""[Publication Type] OR ""popular works""[Publication Type] OR ""portraits""[Publication Type] OR ""practice guideline""[Publication Type] OR ""technical report""[Publication Type] OR OR ""video audio media""[Publication Type] OR ""webcasts""[Publication Type])))))) NOT

Animals[Mesh:noexp])

Filters: Publication date from 1980/01/01; English; Spanish; French

Cochrane Library

"tuberculosis":ti,ab,kw AND "recurrence":ti,ab,kw or "relapse":ti,ab,kw or "reinfection":ti,ab,kw or "reactivation":ti,ab,kw

Filters: Publication date from 1980/01/01

Scielo

(ti:(tuberculosis) OR ab:(tuberculosis)) AND ((ti:(recurren$)or ab:(recurren$)) OR (ti:(reinfección)or ab:(reinfección)) OR (ab:(recaída) OR ti:(recaída)) OR (ti:(reactivación)or ab:(reactivación))

Lilacs

(tw:((tw:((tw:("tuberculosis")) AND (tw:(reinfección)) OR (tw:(recurren*)) OR (tw:(reactivación)) OR (tw:(recaída)) AND (db:("LILACS")))))) NOT (type_of_study:("case_reports")) AND (instance:"regional") AND (la:("es" OR "en"))

Vega V, *et al. Thorax* 2021; 76:494–502. doi: 10.1136/thoraxjnl-2020-215449

Appendix 2: Modified New Castle Ottawa Scale for risk of bias

First outcome: Incidence rate of recurrent TB

	Original scale	Modified scale	Rationale for changes
Selection			
1	Representativeness of the exposed cohort A. Truly representative **(one star)** B. Somewhat representative **(one star)** C. Selected group D. No description of the derivation of the cohort	Representativeness of the **successfully treated** TB patient population A. Truly representative General population **(one star)** B. Somewhat representative Population at probable higher risk of TB (ex. low socio-economic status, miners) **(one star)** C. Selected group (ex. only diabetic or HIV positive patients) D. No description of the derivation of the cohort	Our study question - the rate of recurrent TB- requires a representative population of persons who were successfully treated (either completing TB treatment or cured) and are at risk of relapse or reinfection. Selected populations are those at higher risk of reinfection or relapse, than the general population.
2	Selection of the non-exposed cohort A. Drawn from the same community as the exposed cohort (**one star**) B. Drawn from a different source C. No description of the derivation of the non-exposed cohort	Not applicable as our research question does not include a comparison group.	
3	Ascertainment of exposure A. Secure record (e.g., surgical record) (**one star**) B. Structured interview (**one star**) C. Written self-report D. No description E. Other	Ascertainment of cure A. Confirmed record of cure (smear negative at month 5) **(one star)** B. Confirmed record of treatment completion (the full regimen was completed) C. Unclear record of cure or treatment completion	We consider as “exposure”, “to be at risk of TB after a TB episode that has been cured or successfully treated”. We downgrade the quality for “successfully treated” as patients in this category may not have been cured, and subsequent active TB may actually be a late treatment failure, not a true relapse.

4	Demonstration that outcome of interest was not present at start of study A. Yes (**one star**) B. No	Redundant with item 3; not included	
Comparability			
1	A. Comparability of cohorts on the basis of the design or analysis controlled for confounders B. The study controls for age, sex and marital status (**one star**) C. Study controls for other factors (list) (**one star**) D. Cohorts are not comparable on the basis of the design or analysis controlled for confounders	Not applicable; not included	
Outcome			
1	Assessment of outcome A. Independent blind assessment (**one star**) B. Record linkage (**one star**) C. Self-report D. No description E. Other	Assessment of recurrent episodes A. The recurrent TB episode was defined in the methods as bacteriologically confirmed (**one star)** B. The recurrent TB episode was defined in the methods as bacteriological confirmed or clinical-radiological diagnosis C. The recurrent TB episode was self-reported D. No description	When the recurrent TB episode is bacteriologically confirmed, we can be confident the disease is active TB. Clinical radiological TB diagnoses are less accurate given possible post-TB lung conditions or physicians' inclination to re diagnose TB in case of recurrent chest symptoms
2	Was follow-up long enough for outcomes to occur A. Yes (**one star**) B. No Indicate the median duration of follow-up and a brief rationale for the assessment above:_____	Was follow-up long enough for outcomes to occur A. Yes ≥ 2 years (**one star**) B. No, < 2 years	We propose two years as the cutoff considering it covers the high risk period for relapse and allows sufficient time for reinfections to occur.

3	Adequacy of follow-up of cohorts A. Complete follow-up- all subject accounted for (**one star**) B. Subjects lost to follow-up unlikely to introduce bias- number lost less than or equal to 20% or description of those lost suggested no different from those followed. (**one star**) C. Follow-up rate less than 80% and no description of those lost D. No statement	No change for this item.	
Scale			
	Good quality: 3 or 4 stars in selection domain AND 1 or 2 stars in comparability domain AND 2 or 3 stars in outcome/exposure domain Fair quality: 2 stars in selection domain AND 1 or 2 stars in comparability domain AND 2 or 3 stars in outcome/exposure domain Poor quality: 0 or 1 star in selection domain OR 0 stars in comparability domain OR 0 or 1 stars in outcome/exposure domain	Good quality: 2 stars in selection domain AND 3 in outcome domain Fair quality: 1 star in selection domain OR 2 in outcome domain Poor quality: If 0 stars in selection domain OR 0-1 in outcome domain	We adapted the scale in line with the modifications.

Second outcome: Proportion of reinfections and relapses

	Original scale	Modified scale	Rationale for changes
Selection			
1	Representativeness of the exposed cohort A. Truly representative (**one star**) B. Somewhat representative (**one star**) C. Selected group D. No description of the derivation of the cohort	Representativeness of the **successfully treated** TB patient population A. Truly representative: General population **(one star)** B. Somewhat representative: Population at probable higher risk of TB (ex. By socio-economical status, miners) **(one star)** C. Selected group (ex. only diabetic, HIV) D. No description of the derivation of the cohort	Same as for the first outcome.
2	Selection of the non-exposed cohort A. Drawn from the same community as the exposed cohort (**one star**) B. Drawn from a different source C. No description of the derivation of the non-exposed cohort	Not applicable; not included	
3	Ascertainment of exposure A. Secure record (e.g., surgical record) (**one star**) B. Structured interview (**one star**) C. Written self-report D. No description E. Other	Ascertainment of cure A. Confirmed record of cure (smear negative at month 5) **(one star)** B. Confirmed record of treatment completion (the full regimen was completed) C. Unclear record of cure or treatment completion	Same as for the first outcome
4	Demonstration that outcome of interest was not present at start of study A. Yes (**one star**)	Redundant; not included	

	B. No		
Comparability			
1	Comparability of cohorts on the basis of the design or analysis controlled for confounders A. The study controls for age, sex and marital status (**one star**) B. Study controls for other factors (list) (**one star**) C. Cohorts are not comparable on the basis of the design or analysis controlled for confounders	Not applicable; not included	
Outcome			
1	Assessment of outcome A. Independent blind assessment (**one star**) B. Record linkage (**one star**) Self report C. No description D. Other	Assessment of outcome A. The study use high discriminatory genotyping methods (WGS or MIRU - VNTR) (**one star**) B. The study combines more than 1 method for differentiating relapses and reinfections (**one star**) C. The study uses only one not high discriminatory method for differentiating relapses and reinfections (spoligotyping or RFLP)	The type of test used to discriminate reinfections from relapses is a key item for this outcome. Studies using high discriminatory methods will be less biased. However, the combination of tests can also provide high discriminatory power.

2	Was follow-up long enough for outcomes to occur? A. Yes (**one star**) B. No Indicate the median duration of follow-up and a brief rationale for the assessment above:_____	Was follow-up long enough for outcomes to occur? A. Yes ≥ 2 years (**one star**) B. No, < 2 years	Same as for the first outcome.
3	Adequacy of follow-up of cohorts A. Complete follow-up- all subject accounted for (**one star**) B. Subjects lost to follow-up unlikely to introduce bias- number lost less than or equal to 20% or description of those lost suggested no different from those followed. (**one star**) C. Follow-up rate less than 80% and no description of those lost D. No statement	% availability of DNA fingerprinting for classifying recurrent episodes as relapse or reinfection A. >88% (**one star**) B. ≤88%	We considered completeness of availability of DNA fingerprinting to be a key item for estimates of proportion of reinfections and relapses to be accurate. We established the cut-off point to separate the upper from the 2 lower tertiles of % fingerprinting availability.
Score			
	Good quality: 3 or 4 stars in selection domain AND 1 or 2 stars in comparability domain AND 2 or 3 stars in outcome/exposure domain Fair quality: 2 stars in selection domain AND 1 or 2 stars in comparability domain AND 2 or 3 stars in outcome/exposure domain Poor quality: 0 or 1 star in selection domain OR 0 stars in comparability domain OR 0 or 1 stars in outcome/exposure domain	Good quality: 2 stars in selection AND 3 in outcome Fair quality: 1 star in selection OR 2 in outcome Poor quality: 0 stars in selection OR 0-1 in outcome	Same as for the first outcome.

Appendix 3 Calculation of person-years at risk of recurrent TB

Formula	**Data available**	**Total person-years at risk** of recurrent TB
F1	If incidence rate or Person-Years at risk available	Extracted as reported
F2	If mean follow-up duration for all patients was provided	$\#Successfully\ treated\ patients\ x\ Mean\ follow\ up\ duration\ (years)$
F3	if the mean follow up time is provided only for the patients not lost	$(\#Patients\ not\ lost\ x\ Mean\ follow\ up\ duration\ (years)) + 0.5\ (Planned\ follow\ up\ duration(years)\ x\ \#Patients\ lost$
F4	If mean time to recurrence was provided:	$(\#Recurrent\ patients\ x\ Mean\ time\ to\ recurrence(years)) + 0.5\ (Planned\ follow\ up\ duration(years)\ x\ \#Patients\ lost) + (Planned\ follow\ up\ duration(years)\ x\ \#\ Patients\ without\ recurrence)$
F5	If all the above was not possible	$(\#Patients\ successfully\ treated - 0.5\ x\ (\#Patients\ with\ recurrence + \#Patients\ lost))\ x(Planned\ follow\ up\ duration(years)$

Appendix 4 PRISMA Checklist

Section/topic	#	Checklist item	Reported on page #
TITLE			
Title	1	Identify the report as a systematic review, meta-analysis, or both.	1
ABSTRACT			
Structured summary	2	Provide a structured summary including, as applicable: background; objectives; data sources; study eligibility criteria, participants, and interventions; study appraisal and synthesis methods; results; limitations; conclusions and implications of key findings; systematic review registration number.	2
INTRODUCTION			
Rationale	3	Describe the rationale for the review in the context of what is already known.	3
Objectives	4	Provide an explicit statement of questions being addressed with reference to participants, interventions, comparisons, outcomes, and study design (PICOS).	3
METHODS			
Protocol and registration	5	Indicate if a review protocol exists, if and where it can be accessed (e.g., Web address), and, if available, provide registration information including registration number.	3
Eligibility criteria	6	Specify study characteristics (e.g., PICOS, length of follow-up) and report characteristics (e.g., years considered, language, publication status) used as criteria for eligibility, giving rationale.	3

Vega V, *et al. Thorax* 2021; 76:494–502. doi: 10.1136/thoraxjnl-2020-215449

Information sources	7	Describe all information sources (e.g., databases with dates of coverage, contact with study authors to identify additional studies) in the search and date last searched.	3
Search	8	Present full electronic search strategy for at least one database, including any limits used, such that it could be repeated.	Appendix 6
Study selection	9	State the process for selecting studies (i.e., screening, eligibility, included in systematic review, and, if applicable, included in the meta-analysis).	4
Data collection process	10	Describe method of data extraction from reports (e.g., piloted forms, independently, in duplicate) and any processes for obtaining and confirming data from investigators.	4
Data items	11	List and define all variables for which data were sought (e.g., PICOS, funding sources) and any assumptions and simplifications made.	4
Risk of bias in individual studies	12	Describe methods used for assessing risk of bias of individual studies (including specification of whether this was done at the study or outcome level), and how this information is to be used in any data synthesis.	4
Summary measures	13	State the principal summary measures (e.g., risk ratio, difference in means).	4
Synthesis of results	14	Describe the methods of handling data and combining results of studies, if done, including measures of consistency (e.g., I^2) for each meta-analysis.	4-5
Risk of bias across studies	15	Specify any assessment of risk of bias that may affect the cumulative evidence (e.g., publication bias, selective reporting within studies).	4-5
Additional analyses	16	Describe methods of additional analyses (e.g., sensitivity or subgroup analyses, meta-regression), if done, indicating which were pre-specified.	4-5

Vega V, *et al. Thorax* 2021; 76:494–502. doi: 10.1136/thoraxjnl-2020-215449

RESULTS			
Study selection	17	Give numbers of studies screened, assessed for eligibility, and included in the review, with reasons for exclusions at each stage, ideally with a flow diagram.	5-6 Figure 1
Study characteristics	18	For each study, present characteristics for which data were extracted (e.g., study size, PICOS, follow-up period) and provide the citations.	5-6
Risk of bias within studies	19	Present data on risk of bias of each study and, if available, any outcome level assessment	6-7 Appendix 3
Results of individual studies	20	For all outcomes considered (benefits or harms), present, for each study: (a) simple summary data for each intervention group (b) effect estimates and confidence intervals, ideally with a forest plot.	Appendix 1
Synthesis of results	21	Present results of each meta-analysis done, including confidence intervals and measures of consistency.	Table 2 Table 4
Risk of bias across studies	22	Present results of any assessment of risk of bias across studies.	Figure
Additional analysis	23	Give results of additional analyses, if done (e.g., sensitivity or subgroup analyses, meta-regression [see Item 16]).	Table 2
DISCUSSION			
Summary of evidence	24	Summarize the main findings including the strength of evidence for each main outcome; consider their relevance to key groups (e.g., healthcare providers, users, and policy makers).	7-8

Vega V, *et al. Thorax* 2021; 76:494–502. doi: 10.1136/thoraxjnl-2020-215449

Limitations	25	Discuss limitations at study and outcome level (e.g., risk of bias), and at review-level (e.g., incomplete retrieval of identified research, reporting bias).	9
Conclusions	26	Provide a general interpretation of the results in the context of other evidence, and implications for future research.	10
FUNDING			
Funding	27	Describe sources of funding for the systematic review and other support (e.g., supply of data); role of funders for the systematic review.	17a

Vega V, *et al. Thorax* 2021; 76:494–502. doi: 10.1136/thoraxjnl-2020-215449

Appendix 5 Characteristics of included studies.

Authors	Study setting	Study population	Type of follow-up	Treatment regimen *	TB treatment delivery
Clinical trials					
Aung et al (2012)	Bangladesh	General population	Passive	(2-3)HRZE/$4H_3R_3$	Health facility DOTS
Balasubramaniam et al (1990)	Madras, India	General population	Active	3SRHZ, 3SRHZ/2HZ, 3SHZ/2HZ	Health facility DOTS
Castelo et al (1989)	Sao Paulo, Brazil	General population	Active	2HRZ then, randomly allocated to: 4HR or $4H_3R_2$	Self administered treatment
Chaulet et al (1995)	Algeria	General population	Active	Group S: 2HRZ 4HRZ Group C: 6HRZ	Health facility DOTS
Cohn et al (1990)	Denver, US	General population	Not specified	2HRZS/6HR	Health facility DOTS
Conradie et al (2020)	South Africa	XDR-TB	Non specified	(26weeks) BdqPtoLzd	Health facility DOTS
East African/BMRC (1980)	East Africa and Zambia	General population	Active	For 6 or 8 months 2SHRZ/TH, 1SHRZ/TH, 1SHRZ/S2H2Z2 2SHR/TH-t	Health facility DOTS
East African/BMRC (1981)	East Africa and Zambia	General population	Active	2SHRZ/(9w)HRZ, 2SHRZ/(9w)HR, 2SHRZ/(9w)HZ, 2SHRZ/(9w)H,SHRZ/(9w)H	Health facility DOTS
East and Central African/BMRC (1986)	Kenia, Zambia, Tanzania, Uganda	General population	Active	2SHRZ/4HR - 2SHRZ/4HZ - 2SHRZ/4H - 2SHRZ/6H	Health facility DOTS
El-Sadr et al (1998)	New York, US	HIV-1 infected patients	Active	Induction :2HRZE o 2HRZELfx Continuation: 4HR or 7HR	Health facility DOTS
Fitzgerald et al (2000)	Port au Prince, Haiti	General population	Passive	6 month therapy Initiation phase: HRZ and continuation phase (H_2R_2).	Not specified
Gengiah et al (2014)	South Africa	HIV-1 infected patients	Not specified	2HRZE4/HR in FDC	Health facility DOTS
Gonzalez-Montaner et al (1994)	Argentina, Brazil and Thailand	General population	Not specified	2HRZE/2HR Rifampicin or rifabutin	Health facility DOTS
Gopalan et al (2018)	Chennai, Vellore, and Madurai, south India	HIV-1 infected patients	Active	(1) $2EHRZ_7/4HR_7$; (2) $2EHRZ_7/4HR_3$; and (3) $2EHRZ_3/4HR_3$	Self administered treatment / DOTS
Hong et al (1988)	Seoul, Korea	retreatment	Active	(1) 12RE (2) $12R_3E_3$ (3) $3R_3E_3Z_3/9R_3E_3Z_3S_3$ (4)$3H_3R_3Pto_3/9R_3E_3$	Health facility DOTS
Hong Kong Chest Service (1982)	Hong Kong	General population	Active	6HRSZE3 / 6HRSZ3 / 6HRSE3 / 6HRZE3 / 6HRZE7	Health facility DOTS

Hong Kong Chest Service/BMRC (1991)	Hong Kong	General population	Not specified	2HRSZ/2HRS/2HR , 4HSZ/2HR, 4HRSZ/2HRZ , 6HRZ. Later part of intake, combined vs separate formulation.	Health facility DOTS
Jasmer Lorna et al (2004)	United States and Canada	General population	Active	Rifampin based treament for 6 months	Not specified
Jawahar et al (2013)	Chennai and Madurai, South India	General population	Active	2 $G_3H_3R_3Z_3$ / 2 $G_3H_3R_3$ 2 $M_3H_3R_3Z_3$ / 2 $M_3H_3R_3$ 2 $E_3H_3R_3Z_3$ /4 H_3R_3	Health facility DOTS
Johnson et al (2000)	Kampala Uganda	General population	Active	2HREZ/6HR	Not supervised ambulatory treatment
Johnson et al (2003)	Kampala Uganda	General population	Active	2HRZE/4HR + Interleukin-2	Not specified
Johnson et al (2009)	Kampala, Uganda, Vitória, Brazil; Makati City, Philippines.	General population	Active	2HRZE/2HR - 2HRZE/4HR	Health facility DOTS
Kennedy et al (1996)	Kilimanjaro, Tanzania	General population	Active	4HRCiprofloxacin/2HR 2HRZE/2HRZ/2HR	Health facility DOTS
Kenyan/Zambian/BMRC (1989)	Kenia-Zambia	General population	Not specified	2SHRZ/4TH + Levamisole	Self administered treatment / DOTS
Kohno et al (1992)	Nagasaki	General population	Active	9 months of daily ofloxacin (2 possible doses) or E plusR and H.	Health facility DOTS
Lee et al (2012)	Seoul, South Korea	XDR	Active	Linezolid therapy that started immediately or after 2 months, at a dose of 600 mg per day, without a change in their background regimen.	Health facility DOTS
Madras/BMRC (1989)	Hong Kong	Smear negative	Not specified	Culture positive: 4SHRZ or $4S_3H_3R_3Z_3$ or $6S_3H_3R_3Z_3$. Cultures negative 3SHRZ or $3S_3H_3R_3Z_3$ or $4S_3H_3R_3Z_3$.	Health facility DOTS
Maug et al (2020)	Bangladesh	Smear positive	Active	2EHRZ/4HR y dosis doble Rifampin 2EHRZ/4HR	Health facility DOTS
Merle et al (2014)	Cotonou, Benin; Conakry, Guinea; Nairobi, Kenya; Dakar, Senegal; Durban, South Africa.	General population	Active	Control: 2HRZE 4HR Experimental: 2HRZG 2HRG	Not specified
Mohanty et al (1993)	India	General population	Not specified	2SHRZ/4HR , 2SHZCipro/4HCipro	Not specified
Narayanan et al (2007)	Chennai, India	General population	Active	2HRZE3/6HE	Self administered treatment / DOTS

Vega V, *et al. Thorax* 2021; 76:494–502. doi: 10.1136/thoraxjnl-2020-215449

Parthasarathy et al (1991)	Madras and Bangalore, India	General population	Active	R3: 3HRZS R5: 3HRZS/5$S_2H_2Z_2$ R6: 3HZS/5$S_2H_2Z_2$	Health facility DOTS
Perriens et al (1995)	Kinshasa, DRC	General population	Passive	2HRZ4HR In some HIV positive, the treatment was extended	Not specified
Singapore/BMRC (1981)	Singapore, Chinese, Malay and Indian	General population	Active	2SHRZ/2 or 4 HRZ or 2SHRZ/2 or 4 HR	Health facility DOTS
Singapore/BMRC (1988)	Singapore	General population	Active	(1) 2SHRZ/4H_3R_3 (2) 1SHRZ/5H_3R_3 (3) 2HRZ/4H_3R_3	Health facility DOTS
Singapore/BMRC (1991)	Singapore	General population	Active	Initial phase: (1) 2SHRZ (2) 1SHRZ (3) 2HRZ Continuation phase: 6HR3	Health facility DOTS
Snider et al (1984)	Poland	General population	Not specified	(1) 2HRZ/4H2R2 (2) 2HRZS/4H2R2	Health facility DOTS
Somner et al (1990)	Britain	General population	Not specified	1) 2HRSE/(4-10)HR 2) 2HRSE/(7-16)HR	Not specified
Su et al (2001)	Taipei, Taiwan	General population	Active	(1) 2Rifater+E/Rifinah+E (2) 2HRZE/4HR	Self administered treatment
Swai et al (1988)	Kenya	Isoniazid resistant TB patients	Active	2SZRE/4RE or 2SZRE/7RE	Community DOTS
Tam et al (2002)	Hong Kong	General population	Not specified	2HRZS/HR_3 2HRZS/HRp_1 2HRZS/HRp_1.2/3	Health facility DOTS
Tanzania/BMRC (1985)	Africa	General population	Active	2 SHRZ/4TH /// 2SHRZ/4H	Health facility DOTS
Teo et al (1999)	Singapore	General population	Active	2SHRZ/4H(3)R(3) /// 1SHRZ/5H(3)R(3) /// 2HRZ/4H(3)R(3)	Health facility DOTS
Tuberculosis Research Centre (1981)	Madras, India	General population	Passive	2 weeks EHS plus → EH or E_2H_2 or E_1H_2 or E_1H_1	
Tuberculosis Research Centre (1997)	Madurai, South India	General population	Not specified	(1) 2HRZE/6EH (2) 2$E_2H_2R_2Z_2$/4EHR (3) 2$H_2R_2Z_2$/4H_2R_2	Self administered treatment / DOTS
Velayutham et al (2020)	Chennai, Madurai and Vellore in South India.	General population	Non specified	3MfxHRZE / 2MfxHRZE/2Mfx3H3R3 / 2HRZE/4HR	Health facility DOTS
Wu et al (2015)	Taiwan	General population	Active	The FDC group received Rifaters and E for the first two months, followed by Rifinahs (H + R) and E for an additional four months or longer. Theseparate formulation (SF) group received 2HRZE4HRE.	Health facility DOTS

Yan et al (2018)	China	Retreatment patients	Active	2HREZS/ 6HRE - 5MxfPARfbEZ	Health facility DOTS
Zierski et al (1981)	Poland	General population	Not specified	Regimen A (6 HRE) Regimen B (2 HRElHR) Regimen C (2 HRE/lHRE) Regimen D (2 HRE/lHRE)	Not specified
Observational prospective studies					
Anaam et al (2012)	Yemen	General population	Passive	4HRZE/6HE	Health facility DOTS
Anaam et al (2019)	Yemen	General population	Active	2HRZE/6HR	DOTS Comunitario
Anh et al (2020)	Vietnam	MDR	Active	(4-6)LfxKmCfzPtoEHZ/5LfxCfzEZ	Not specified
Aung et al (2014)	Bangladesh	MDR	Active	FX, E, Z, and clofazimine throughout, supplemented during the minimum 4-month intensive phase by kanamicin, prothionamide, and H.	Health facility DOTS
Banda et al (2000)	Southern Region of Malawi	Smear negative	Active	2ERHZ/6EH	Health facility DOTS
Becerra et al (2010)	Lima, Peru	MDR TB patients	Active	MDR-TB regimen	Health facility DOTS
Bechan et al (1997)	Durban, South Africa	General population	Not specified	(26weeks) H2R2Z2S2	Health facility DOTS
Cao et al (1988)	China	General population	Active	2H3R3Z3S3/4H3R3, 2H3R3Z3E3S3/6H3R3E3	Health facility DOTS
Chaisson et al (1996)	Cité Soleil, Haiti	General population	Pasive	(8weeks)HRZE/(18weeks)HR	Health facility DOTS
Chang et al (2004)	Hong Kong	General population	Pasive	2HRZ/4HR 2RZE/4RE	Health facility DOTS
Charalambous et al (2008)	Free State Province, South Africa	South African gold miners	Active	Rifampin based short-course chemotherapy regimen(not specified)	Facility based DOTS
Chien et al (2014)	Taiwan	Isoniazid resistant TB patients	Passive	2HRZE/4HR	Health facility DOTS
Choi et al (2014)	South Korea	General population	Active	Not specified. 9-month treatment for susceptible TB, indivual regimen for resistant patients.	Not specified
Connolly et al (1999)	KwaZulu-Natal, South Africa	General population	Passive and Active	HRZE given in hospital (median 17 days), followed by 2H2R2Z2E2 to 6H2R2	Health facility DOTS and community based DOTS
Cowie et al (1989)	South Africa	Gold miners	active	Variable. Rifampin based regimens	Health facility DOTS

Crampin et al (2010)	Karonga, Malawi	General population	Active	Smear-positive patients: Prior to 1997: 2SHRZ/6TH. 1997-2001: 2SHRZ/6EH After 2001: 2SHRZ/6SH. Smear-negative patients: Prior to 1997: 1SHT/11TH. 1997-2001: 1SHE/11EH. After 2001: 2HRZ/6EH	Not specified
d'Arc et al (2008)	Recife, Brazil	General population	Passive	2HRZ/4HR	Not specified
Dutt et al (1984)	Arkansas, US	General population	Active	1HR/8H3R2	Self administered treatment /DOTS
Dutt et al (1990)	Arkansas, US	General population	Pasive	1HR(Rifamate)/5HR	Self administered treatment /DOTS
Escudero et al (2006)	Hospital La Fuenfría, Madrid, Spain	MDR	Active	Empirical treatment based on prior treatment. One parenteral drug plus at least three oral drugs. "The parenteral drug was used during the first 6 months, as follows: 5 days a week for 2 months, 3 days a week for the next 2 months and 2 days a week for the last 2 months. Definitive therapeutic regimens were determined according to the DST results. The planned treatment duration was 18 months, or 12 months of continual negative cultures after the first two negative cultures."	Not specified
Fox et al (2018)	Vietnam	General population	Mixed	2HRZE/4HR	Health facility DOTS
Garcia Martinez et al (1996)	North-western region of Leon-Chinandega, Nicaragua	General population	Active	2SRHZ/ 6TH (157 patients) 2STH/10TH (90 patients)	Health facility DOTS
Guerra-Assunção et al (2015)	Karonga, Malawi	General population	Active	1996-2001 New smear-positive patients: 2SHRZ/6HE. New smear-negative patients:1SEH/11HE 2001-2007: 2HRZE/6HE After 2007: 2HRZE/4HR	Not specified
Hang et al (2015)	Hanoi, Vietnam	General population		2S(E)HRZ/6HE	Health facility DOTS
Hawken et al (1993)	Nairobi, Kenya	HIV-1 infected patients	Active	1TSH11TH 1TSH11TH + Another antituberculosis drug. 1HRZS 1HRZ 4TH	Not specified
Hesseling et al (2010)	Western Cape Province, South Africa	Non HIV-infected patients	Active	2RHZE/4HR	Facility based DOTS

				*The intensive phase was prolonged to 3 months if smear conversion had not occurred at 2 months	
Houben et al (2012)	Karonga, Malawi	HIV-patients	Active	Smear positive before 1997: 2SHRZ/6TH From 2001: 2EHRZ/6EH Smear negative before 1997: 1SHT/11TH From 2001: 1SHE/11HE Since 2007: 2HRZE/4HR	Not specified
Huyen et al (2013)	Mekong River Delta, Vietnam	General population	Active	2HRSZ/6HE	Not specified
Jasmer et al (2004)	San Francisco, US	General population	Passive	6 months of standard therapy	Health facility DOTS / Self administered treatment
Jimenez Corona et al (2013)	Orizaba, Veracruz, Mexico	General population	Active	1995 and 1998 New cases: 2HRZ/4HR Retreatment cases: 2HRZ/4HR plus E or S. After 1998 New cases: 2HRZE/4HR Retreatment cases: 2HRZES(/1HRZE/5HRE.RZE/5HRE.	Community based DOTS
Karagaoz et al (2009)	Istambul, Turkey	MDR	Not specified	"Second-line drugs, occasionally, an aminoglycoside (amikacin, capreomycin), a quinolone derivative (ofloxacin, ciprofloxacin), prothionamide and cycloserine were used in treatment of MDR- TB patients and some of the first line drugs, such as Z and E, thought to be susceptible, were included in the new regimen. If quinolone derivatives and prothionamide had already been used in previous regimen, drugs such as clofazimine, para-aminosalycylic acid (PAS), T, amoxicillin-clavulanic acid and capreomycin were included in the regimen."	Health facility DOTS
Kassim et al (1995)	Abidjan, Nigeria	General population	Active	2HRZ4HR	Self administered treatment
Kuaban et al (2015)	Cameroon	MDR	Active	4KmPtoCfzHEZ/8HKm	Health facility DOTS
Lawal et al (2019)	South africa	General population	Active	Standard regimen	Not specified
Lee et al (2014)	Taiwan	Diabetes	Passive	Standard regimen	Health facility DOTS
Lee et al (2020)	Seoul, South Korea	Cavitary tuberculosis	Active	2HRZE/4HRor 2HRZE/ 7HR	Not specified

Malherbe et al (2020)	Cape Town, South Africa	General population	Active	Standard regimen	Not specified
Mathur et al (2020)	Hyderabad, Telangana, India	Smear positive pulmonary TB patients	Active	Standard regimen	Not specified
McGreevy et al (2012)	Post-au-Prince, Haiti	HIV-1 infected recurrent TB patients		2HRZES/1HRZE/5HRE	Not specified
Miles et al (1984)	Nong Samet, Cambodia	Refugees	Active	2HRSZ/4HR	Health facility DOTS
Narayanan et al (2010)	Chennai and Madurai, India	HIV-infected patients	Active	HIV-infected patients received 2H3R3Z3E3/4-7R3H3. Some HIV-negative patients were treated with the same regimen of 2HRZE/4R3H3 whereas, others, received a regimen containing 3HRZOfloxacin/1 or 2 H3R3	Facility based DOTS
Nolan et al (2002)	Seatle, US	isoniazid-resistant tuberculosis	Pasive	6HREZ	Self administered treatment / DOTS
Palmero et al (2004)	Buenos Aires, Argentina	MDR	Active	Individual regimens: E, Z, S and/or second line drugs	Self administered treatment / DOTS
Pandey et al (2020)	India	General population	Active	2HRZE/4HR	Health facility DOTS
Peetluk et al (2019)	Brazil	General population	Active	2HRZE/4HR	Health facility DOTS
Perez-Guzman et al (2002)	Mexico	Drug resistant	Active	Treatment according DST rsults	Self administered treatment
Perriens et al (1991)	DRC		Pasive	2HST/10TS	Not specified
Pettit et al (2011)	Tennesee, US	General population	Passive	"National and international guidelines for treatment of drug-susceptible TB recommend a 6-month rifamycin-based regimen. In USA treatment is extended to 9 months in patients with cavitary pulmonary TB and a positive sputum culture after 2 months or silico tuberculosis."	Facility based DOTS
Piubello et al (2014)	Niamey, Niger.	MDR	Active	4GfxCfzEZKmPtoH/8GfxCfzEZ	Health facility DOTS
Prasad et al (2004)	Uttar Padresh, India	MDR	Active	Kanamycin (initial 4-6 months), ethionamide, H, PAS and cycloserine for a minimum period of two years.	Health facility DOTS

Prasad et al (2008)	India	General population	Active	Cat I, Cat II, Cat III	Health facility DOTS
Pulido et al (1997)	Madrid, Spain	HIV-patients	Passive	Regimen that include H a R for 6 or more months supplemented with Z,E,S or combination for the first 2 months.	Not specified
Reis et al (1990)	Brazil	Pediatric population	Active	6HR	Not specified
Schwœbel et al (2020)	Benin, Burkina Faso, Burundi, Cameroon, Central African Republic, Côte d'Ivoire, Democratic Republic of Congo, Niger and Rwanda.	General population	Active	4-6Knm,Cfz,Mfx,HZPto/5MfxZCfz	Health facility DOTS
Shen et al (2017)	Shanghai, China	General population	Passive	Standard regimen	Not specified
Sonnenberg et al (2001)	Gauteng, South Province, South Africa	South African mineworkers	Active	At least 6 months of 2HRZE/4HR.	Health facility DOTS
Spagnolo et al (1982)	US	General population	Not specified	2HRE/7HR	Self administered treatment
Suryanto et al (2008)	South Sulawesi Province, Republic of Indonesia	General population	Active	2HRZE/3H3R3 4FDC (225 mg INH, 450 mg RMP, 1200 mg PZA and 825 mg EMB.) was used and 2FDC (450 mg INH and 450 mg RMP)	Health facility DOTS
Swaminathan et al (2008)	Tambaram, Chennai	HIV-patients	Active	2EHRZ3/4RH3	DOTS comunity
Thomas et al (2005)	Tamil Nadu, India	General population	Active	2H3R3Z3E3/4H3R3	Health facility DOTS
Thomas et al (2019)	Chennai and Pune, India	General population	Active	(1) daily (daily in both intensive and continuation phases)—2EHRZ7/4HR7; (2) part-daily (daily intensive phase and intermittent continuation phase)— 2EHRZ7 /4HR3 ; and (3) intermittent (thrice weekly throughout)—2EHRZ3/4HR3	Health facility DOTS
Van Deun et al (2004)	Bangladesh, India	MDR-TB infected patients	Passive	New cases received 2HRZE/6HT. Retreatment cases received 2SEHRZ/1EHRZ/5EHR.	Health facility DOTS
Van Deun et al (2010)	Bangladesh	MDR	Active	"All regimens were based on a fluoroquinolone (ofloxacin or, in regimen 6, gatifloxacin), kanamycin, and prothionamide as the core drugs, supplemented by other potentially active	Health facility DOTS

Vega V, *et al. Thorax* 2021; 76:494–502. doi: 10.1136/thoraxjnl-2020-215449

				companion drugs (first-line drugs and clofazimine)."	
Velayutham et al (2018)	Tamil Nadu, Karnataka, Delhi, Maharashtra, Madhya Pradesh and Kerala, India	General population	Active	(2 H3R3Z3E3 / 4H3R3)	Health facility DOTS
Vree et al (2007)	Northern Vietnam	General population	Active	The standard treatment regimen for new patients consists of daily 2SHRZ/6HE).	Health facility DOTS
Westerlund et al (2015)	Lima, Peru	General population	Active	Standard regimen	Not specified
Yoshiyama et al (2010)	Khatmandu Valley, Nepal	Retreatment patients	Active	2HRZSE/1HRZE/5HRE	Health facility DOTS
Zheng et al (2020)	China	General population		Standard regimen	Health facility DOTS
Observational retrospective studies					
Banu et al (2012)	Chennai, India	General population	Active	(2 H3R3Z3E3 / 4H3R3)	Health facility DOTS
Chiang et al (2006)	Taipei, Taiwan	MDR TB patients	Active	Individualized MDR TB 1	Self administered treatment
Ciza et al (2020)	Burundi	Rifampicine resistance	Pasive	(4-5)KmMfxPtoCfHZE/5MfxCfzZE	Health facility DOTS
Dale et al (2017)	Victoria, Australia	General population	Passive	6-month standard regimen	Self administered treatment
Dangisso et al (2018)	Dale and Yirgalem, Ethiopia	Smear positive	Active	Standard regimen	Not specified
Datiko et al (2009)	Dale and Wonsho, Sidama, Ethiopia	General population	Active	Standard regimen	Health facility DOTS
Decro et al (2020)	Bangladesh	RR TB patients	Passive	2KmCfxGfxEHPZ / 5 GfxEZCfz (Gfx and H in high dose regimen)	Not specified
Gelmanova et al (2015)	Tomsk, Russian Federation	MDR TB patients	Passive	All patients were treated with regimens that included second-line drugs, fluoroquinolones and parenteral agents (not specified)	Not specified
Glynn et al (2010)	Gauteng, South Africa	Miners	Passive	2HRZE 4HR 2HRZES, 1HRZE, and 5HRE	Health facility DOTS
Guglielmetti et al (2016)	Bligny, Pitié Salpêtrière and Bichat Hospitals, France	MDR	Passive	According to patient include bedaquiline	Not specified
He et al (2010)	Heilongjiang, China	MDR	Passive	Second line treatment	Health facility DOTS

Jo et al (2014)	Seoul, South Korea	General population	Passive	2HRZE/4HRE	Self administered treatment
Kim et al (2017)	South Korea	General population	Not specified	Culture positive: 4SHRZ or 4S3H3R3Z3 or 6S3H3R3Z3 . Cultures negative 3SHRZ or 3S3H3R3Z3 or 4S3H3R3Z3.	Health facility DOTS
Lee et al (2011)	Seoul, South Korea	MDR TB patients	Not specified	Drug resistant TB regimen	Not specified
Lee et al (2015)	Seoul, South Korea	H resistant TB patients	Passive	Drug resistant TB regimen	Not specified
Liu et al (2020)	Beijing	General population	Pasive	WHO recommendation	Health facility DOTS
Luzze et al (2013)	Kampala, Uganda	General population	Active	94%: 2HRZE/4-6RZ 2HRZE/6EZ	Not specified
Ma et al (2018)	Beijing Chest Hospital, , Shenyang Chest Hospital	Diabetes Mellitus 2	Passive	2HREZS/6HRE	Not specified
Marx et al (2014) / Dippenar et al (2019)	Cape Town, South Africa	General population	Active	Standard first-line treatment	Facility based DOTS
Migliori et al (2002)	Ivanovo Oblast, Russsian Federation	MDR TB patients	Passive	Cat-I, Cat-II, Cat-III	Not specified
Moosazadeh et al (2015)	Iran	General population	Passive	Standard regimen	Not specified
Moreno-Martinez et al (2007)	Región Soconusco, Chiapas, México	General population	Passive	Not specified	Not specified
Nahid et al (2007)	San Francisco, US	HIV-1 infected patients	Passive	Rifamyicin based 6 month regimen. 32 patients on ARV took rifabutin	Facility based DOTS
Nettles et al (2004)	Baltimore, US	General population	Passive	" Al patients were treated with 15 daily doses of 4-drug therapy (H, R or rifabutin, Z, and E in standard doses. Patients subsequently received twice-weekly- 4-drug therapy for 6 weeks, followed by a course of twice-weekly I and R or rifabutin".	Facility based DOTS
Ormerod et al (2002)	Blackburn, Hyndburn and Ribble Valley districts, UK	General population	Passive	2RHZ(E)/4RH	Not specified
Park et al (2019)	South Korea	Rheumatological disease patients		2HRZE/4HR	Not specified
Picon et al (2007)	Rio Grande do Sul, Porto Alegre, Brazil	General population	Passive	2HRZ/4HR Other regimens used, R always included.	Self administered treatment

Piubello et al (2020)	Niamey, Maradi and Zinder; Niger	RR/MDR patients	Active	MDR TB regimen	Health facility DOTS
Seon et al (2014)	Republic of Korea	General population	Active	2HRZE/7HRE	Not specified
Shin et al (2006)	Peru	MDR	Mixed	"Regimens generally included at least 5 drugs to which the infecting isolate was susceptible, and treatment duration was 18–24 months."	Not specified
Slutkin et al (1988)	San Francisco	General population	Passive	Treatment regimen was 3HRE/6HR.	Health facility DOTS
Sun et al (2017)	Henan Province, China	General population	Active	2HRZE4HR Retreatment: 2HRZE/6HRE	Health facility DOTS
Van der Heijden et al (2018)	Durban, South Africa	General population	Passive	New drug-susceptible TB patients received 2HREZ/4HR.	Not specified
Van Deun et al (2006)	Bangladesh	General population	Passive	2EHRZ/6HT control 3EHRZ/6HT extension group	Not specified
Vieira et al (2017)	Carapicuiba, Sao Paulo Brazil	General population	Passive	Standard treatment	Health facility DOTS
Wang et al (2015)	Taiwan	HIV-patients	Active	2HRZE/6HR	Health facility DOTS
Wu et al (2015)	Changning, Shanghai, China	General population	Passive	2HRZE(S)/4HR	Not specified
Xia et al (2014)	Beijing, China	General population	Passive	2H3R3Z3E3/4H3R3 or 2HRZE/4HR	Health facility DOTS
Yen et al (2014)	Taipe, Taiwan	General population	Passive	WHO recommended treatment	Health facility DOTS
Yoshiyama et al (2014)	Fukujuji Hospital, Japan	MDR TB patients	Passive	E, Z, Cm (until 1995) or aminoglycoside, fluoroquinolone (Ofx in 1990s and Gfx or Lfx in the 2000s), Eto, Cs, an PAS. The minimum duration of treatment was 2 years	Not specified
Zhdanov et al (2017)	Israel	General population	Passive	Standard treatment	Health facility DOTS
TB program databases					
Bandera et al (2001)	Lombardy region, Milan, Italy	General population	Passive	6 months of combination therapy (not specified)	Not specified
Cacho et al (2007)	Madrid, Spain	General population	Passive	2HRZ/4HZ or 2HRZE / 4HR	Not specified
Caminero et al (2001)	Gran Canaria, Spain	General population	Active	2HRZ/4HR	Facility based DOTS
Das et al (1995)	Madras India	General population	Unknown	Not specified	Not specified

Das et al (1993)	Madras India	General population	Unknown	Not specified	Not specified
Dobler et al (2009)	New South Wales, Australia	General population	Passive	Drug-sensitive TB: 2HRZE/4HR MDR TB: Second line TB drugs for 1 or 2 years	Facility based DOTS
ElSahly et al (2004)	Houston and Harris County, Texas, US	General population	Active	Not specified	Community based DOTS
Folkvardsen et al (2020)	Denmark	Patients infected with DKC2 strain	Not specified	Not specified	Not specified
Lourenco et al (2000)	Rio de Janeiro, Brasil	HIV-infected patients	Passive	2HRZE/7HR	Not specified
Parvaresh et al (2018)	New South Wales	General population	Passive	Not specified	Health facility DOTS
Quy et al (2002) / Lan et al (2003)	Ho Chi Min, Vietnam	General population	Not specified	2SRHZ/6HE	Facility based DOTS
Rosser et al (2018)	Lecistershire and Rutland, UK	General population	Not specified	2EHRZ3/4RH3	Not specified
Schiroli et al (2015)	Lombardy region, Milan, Italy	General population	Passive	Not specified	Not specified
Shamputa et al (2007)	Bangladesh	General population	Passive	New smear-positive cases received a daily Category I: 2HRZE/6HT. Retreatment patients were treated with Category II: 2SHREZ/1HREZ/5H3R3E3	Not specified
Shen et al (2006)	Shanghai, China	General population	Active	Not specified	Community DOTS
Umubyeyi et al (2007)	Rwanda	General population	Active	New smear-positive cases received standard Category I regimen, consisting of 2HRZE/4H3R3. Retreatment patients with at least one month of a drug intake were treated with Category II 2HRZES/1ZE/5H3R3E3	Not specified
VanRie et al (1999)	Cape Town, South Africa	General population	Passive	New cases were treated with H, ryfampin, and Z for 6 to 8 months, while retreatment patients received a four-drugs regimen.	Health facility DOTS

*The number before the acronym represents the number of months. The subscript represents the weekly dose, if none, it is taken daily, H=isoniazid, R=rifampicin, Z=pyrazinamide, E=Ethambutol, S=Streptomycin, TH=Thiacetazone, Bdq=Bedaquiline, Pto=pretomonid Lnz=linezolid, Mfx=Moxifloxacin, Cfz=clofazimine, Km=kanamycin, Ofx=ofloxacin, Lfx=levofloxacin, Cs=cycloserine, Eto=ethionamide, Gfx=Gatifloxacin, PAS =*p-aminosalicylic acid*

Appendix 6. Individual data of included studies

Table S1 Individual outcomes of cohort studies and clinical trials included in the review and calculation of person-years of follow up

	Extracted by study											Calculated			WHO estimates
Author	Nº of patients successfully treated (denominator)	Nº of TB recurrent episodes (numerator)	Death	Moved	Other	Loss to follow up	Total censored	Planned follow-up (years, unless specified)	Person years of follow up	Mean follow-up (years)	Mean time to recurrence (years)	Total person yearsears calculated	Recurrent TB incidence calculated (per 100 pyear)	Formula used *	Background incidence per 100,000 pop
Clinical trials															
Castelo et al (1989)	506	27	-	-	-	-	0	1	-	-	-	4923	5.48	F5	62.3
Chaulet et al (1995)	228	1	-	-	-	21	21	2	-	2.00	-	435	0.23	F3	49.0
Cohn et al (1990)	108	2	7	-	-	-	7	3	-	-	2.58	313	0.64	F4	9.2
East African/BMRC (1980)	737	57	45	-	15	45	105	2	-	-	-	1312	4.34	F5	103.1
East African/BMRC (1981)	551	131	6	-	3	31	40	1.2	-	-	-	543	24.12	F5	212.0
Fitzgerald et al (2000)	274	15	-	-	-	-	0	-	542	-	-	542	2.77	F1	123.9
Gengiah et al (2014)	51.00	8	-	8	-	-	-	-	113	-	1.75	113	7.07	F1	820.0
Gonzalez-Montaner et al (1994)	467	5	-	-	-	116	116	2	-	-	-	813	0.62	F5	39.9/48.2/82.3
Gopalan et al (2018)	241	16	-	-	-	14.00	14	1	225	-	-	225	7.12	F1	234.0
Hong et al (1988)	352	44	-	-	-	192	192	2	-	-	-	468	9.40	F5	254.7
Hong Kong Chest Service (1982)	792	22	18	-	3	20	41	1.5	-	-	-	1141	1.93	F5	150.3
Hong Kong Chest Service/BMRC (1991)	888	34	11	12	6	27	56	2.5	-	-	-	2108	1.61	F5	145.4
Jasmer Lorna et al (2004)	1229	81	-	-	-	-	0	2	-	-	-	2377	3.41	F5	6.7
Jawahar et al (2013)	380	40	-	-	-	-	0	2	-	-	-	720	5.56	F5	279.0
Johnson et al (2000)	225	18					87	2	335			335	5.36	F5	117.0
Johnson et al (2009)	388	18	4			2	6	2	-	-	5.00	824	0.35	F4	274.0
Johnson et al (2003)	95	2	-	-	-	-	0	6	-	-	-	564	2.18	F5	248.0
Kennedy et al (1996)	168	7	2	10			12	0.5	-	-	-	79	8.83	F5	95.7

Kenyan/Zambian/BMRC (1989)	502	30	3	-	1	42	46	2	-	-	-	928	3.23	F5	128.5
Kohno et al (1992)	92	0	-	-	-	16	16	2	-	-	-	168	0.00	F5	46.3
Lee et al (2012)	13	0	-	-	-	-	0	1	-	-	-	13	0.00	F5	94.0
Madras/BMRC (1989)	1620	82	19	76	2	21	118	4.5	-	-	-	6840	1.20	F5	150.2
Merle et al (2014)	1356	148	37	-	20	172	229	2.0	-	-	-	2335	6.34	F5	820.0
Mohanty et al (1993)	35	4	-	-	-	-	0	24	-	-	-	792	6.06	F5	120.0
Narayanan et al (2007)	413	20	-	-	-	-	0	2	-	-	-	806	2.48	F1	289.0
Parthasarathy et al (1991)	688	85	7	22	4	-	33	24 months after treatment start	-	-	-	1046	8.13	F5	152.2
Perriens et al (1995)	420	19	37	-	-	117	154	1.5	-	-	-	501	3.80	F5	91
Singapore/BMRC (1988)	350	11	13	2	3	4	22	2	-	-	-	667	1.65	F5	72.1
Singapore/BMRC (1991)	287	10	5	1	-	-	6	1.5	-	-	-	419	2.39	F5	98.5
Snider et al (1984)	272	5	-	-	-	-	0	2	-	-	-	539	0.93	F5	61
Su et al (2001)	51	1	-	-	-	-	0	2	-	-	-	101	0.99	F5	33.7
Swai et al (1988)	224	8	7	-	-	39	46	2	-	-	-	394	2.03	F5	33.00
Tam et al (2002)	534	46	6	-	-	-	6	4.5	-	-	-	2286	2.01	F5	109.3
Tanzania/BMRC (1985)	224	14	2	-	-	17	19	2	-	-	-	415	3.37	F5	62
Teo et al (1999)	271	14	14	-	-	10	24	5	-	-	-	1260	1.11	F5	76.3
Tuberculosis Research Centre (1981)	172	52	-	-	-	-	0	4	-	-	-	584	8.90	F5	300.0
Tuberculosis Research Centre (1997)	787	65	1	-	-	3	4	2	-	-	-	1505	4.32	F5	117.6
Wu et al (2015)	98	0	-	-	-		0	1	-	-	-	98	0.00	F5	82.0
Yan et al (2018)	661	51	-	-	-	215	215	5	-	-	-	2640	1.93	F5	73.0
Zierski et al (1981)	363	54	13	-	-	33	46	2.5	-	-	-	783	6.90	F5	451.0
Conradie et al (2020)	100	2	1		1	1	3	0.5				48.75	4.10	F5	146.00
Maug et al (2020)	638	5				38	38	1				616.50	0.81	F5	221.00
Velayutham et al (2020)	1180	84					0	2				2276.00	3.69	F5	234.00
Cohort studies															
Anaam et al (2012)	814	44	16	-	-	24	40	1	-	-	0.55	774	5.68	F5	25
Aung et al (2014)	435	6	-	-	-	-	0	2	-	-	-	864	0.69	F3	221
Banu et al (2012)	238	14	-	-	-	-	0	2	-	-	-	462	3.03	F4	234
Becerra et al (2010)	442	16	85	-	-	40	125	2.0	646		0.53	646	2.48	F5	183.00
Bechan et al (1997)	348	18		33	-	-	33	-		1.75	1.03	621	2.90	F5	212.7
Cao et al (1988)	649	28	39	1	-	-	40	2	-	-	-	1230	2.28	F1	29.5
Chaisson et al (1996)	341	13	-	-	-	-	0	3.5	-	-	-	1157	1.12	F1	145.1
Chang et al (2004)	12183	113	-	-	-	-	-	2.0	-	-	8.90	25146	0.45	F5	36.4
Charalambous et al (2008)	609	42	-	-	-	-	0	31 -Mar-2002	7096	1.02	-	7096	0.59	F1	585.00

Chiang et al (2006)	153	10	-	-	-	-	0	6	493	-	-	494	2.02	F5	8.70
Chien et al (2014)	328	4	-	-	-	-	-	2	-	-	-	652	0.61	F5	85.00
Choi et al (2014)	289	17	20	-	-	11	31	3.3	-	0.83	-	869	1.96	F5	88
Connolly et al (1999)	403	19	58	78	-	-	136	-	499	1.20	-	499	3.81	F5	323
Cowie et al (1989)	2776	378	-	-	-	-	0	3	5442	-	-	5442	6.95	F5	175.4
Crampin et al (2010)	584	53	-	-	-	-	0	10.8	1646	-	-	1646	3.22	F5	392.00
d'Arc et al (2008)	754	37	43	-	-	-	43	5.0	-	-	-	3570	1.04	F4	104
Dale et al (2017)	3885	20	-	-	-	-	0	31/Dec/ 2014	-	5.70	2.66	2227	0.90	F5	6.5
Dangisso et al (2018)	1688	101	-	-	-	-	0	-	-	-	-	6645	1.52	F5	310
Datiko et al (2009)	368	15	-	-	-	-	0	-	1463	3.87	-	1463	1.03	F5	168
Dobler et al (2009)	3731	15	-	-	-	-	0	31/Dec/ 2006	-	5.70	1.42	2122	0.71	F5	6.3
Picon et al (2007)	610	26	-	-	-	-	0	-	-	7.70	-	5200	0.50	F5	45
Dutt et al (1984)	751	15	105	45	-	-	150	7	-		-	4680	0.32	F5	11.8
Dutt et al (1990)	211	5	34	6	-	-	40	2	401	3.75	-	401	1.25	F5	11.8
Escudero et al (2006)	21	0	-	-	-	-	0	2	-	-	-	42	0.00	F5	23
Fox et al (2018)	9825	498	198	-	-	-	198	2	-	-	-	18954	2.63	F1	133
Garcia Martinez et al (1996)	204	3	5	-	-	10	15	17-32 months	388	-	2.05	388	0.77	F5	84.00
Gelmanova et al (2015)	399	27	30	20	41	15	106	6	1320	3.53	-	1321	2.04	F5	80.2
Glynn et al (2010)	646	164	-	-	-	-	0	31-Dec- 2004	1408	-	-	1408	11.65	F5	245.4
Guerra-Assunção et al (2015)	1471	139	-	-	-	64	64	-	6306	-	-	6306	2.20	F5	153
Guglielmetti et al (2016)	36	0	-	-	-	13	13	2	-	-	-	59	0.00	F5	9
Hang et al (2015)	413	30	-	-	-	10	10	1.3	-	1.33	0.38	544	5.52	F5	164.00
Hawken et al (1993)	196	11	12	-	19	-	31	-	2598	1.25	8.00	2598	0.42	F5	72.3
He et al (2010)	194	63	12	56	7	20	95	4	-	4.00	-	586	10.75	F5	94
Hesseling et al (2010)	211	22	5	10	-	21	36	2.0	-	-	-	364	6.04	F5	841
Houben et al (2012)	1133	103	309	-	-	105	414	30-Jun-2011	4353	-	-	4353	2.37	F5	75
Huyen et al (2013)	1073	35	20	-	-	5	25	1.5	1658	1.53	-	1658	2.11	F5	172
Jasmer et al (2004)	305	3	-	-	-	36	36	1	-	-	-	286	1.05	F5	5.7
Jimenez Corona et al (2013)	1019	74	-	-	-	-	0		-	5.14	-	5238	1.41	F5	21
Jo et al (2014)	317	6	-	-	-	-	0	1	-	-	0.30	313	1.92	F5	85
Karagaoz et al (2009)	102	0	-	-	-	13	13	2	-	1.60	-	191	0.00	F5	33
Kassim et al (1995)	523	20	-	-	-		0	1.5	-	-	-	770	2.60	F3	216
Kim et al (2017)	A: 30 B: 56	1	-	-	-	-	-	-	-	A: 1.08 B: 0.96	1.48	86.38	1.16	F4	92

Kuaban et al (2015)	134	0	-	-	-	17	17	1	-	-	-	126	0.00	F5	271
Lawal et al (2019)	53	3	-	-	-		0	0.5	-	-	0.42	26	11.43	F5	567
Lee et al (2011)	90	4	-	-	-		0	2	-	3.23	1.10	290	1.38	F1	77.00
Lee et al (2014)	21939	305	-	-	-	-	-	31-Dec- 2010	-	3.00	1.40	62500	0.49	F1	89.00
Lee et al (2015)	133	5	-	-	-	-	0	-	-	0.53		71	7.05	F5	88
Luzze et al (2013)	1701	171	-	-	-	-	0	-	-	1.24	0.54	2036	8.40	F1	400
Ma et al (2018)	58	16	-	-	-	0	0	3	-	-	-	150	10.67	F5	64
McGreevy et al (2012)	120	5	8	-	-	5	13	3	-	4.50	1.42	348	1.44	F5	238.00
Migliori et al (2002)	21	5	-	-	-	-	0	-	-	0.54	0.86	17	29.52	F5	89
Moreno-Martinez et al (2007)	310	39	-	-	-	-	0	-	312	1.17	-	312	12.49	F5	21.00
Nahid et al (2007)	558	16	53	26		128	207	1	4489	-	-	4489	0.36	F5	8.70
Nettles et al (2004)	407	14	-	-	-	-	0	1	-	-	-	400	3.50	F5	8.70
Nolan et al (2002)	42	2	-	-	-	-	0	2	-	-	-	82	2.44	F4	8.6
Palmero et al (2004)	73	7	-	-	-	-	0	1	-	-	-	70	10.07	F5	34.6
Park et al (2017)	51	8	-	8	-	-	8	-	113		1.75	113	7.07	F5	820
Perez-Guzman et al (2002)	31	1	3	-	-	11	14	5	-	-	-	118	0.85	F5	18.3
Perriens et al (1991)	332	20	-	-	-	49	49	1	244	0.75 / 0.89	-	244	8.19	F5	300.00
Pettit et al (2011)	1431	20	-	-	-	-	0	1	-	4.50	1.14	6440	0.31	F5	5.1
Piubello et al (2014)	58	0	5	4	-	-	9	2	-	-	-	107	0.00	F5	118
Prasad et al (2004)	29	2	-	-	-	4	4	31-Apr- 2004	-	1.33	-	39	5.33	F5	285
Prasad et al (2008)	212	11	-	-	-	-	0	1	-	-	-	207	5.17	F5	285.00
Pulido et al (1997)	189	15	-	-	-	-	0	-	-	2.63	-	556	2.70	F1	17.5
Reis et al (1990)	117.00	0	-	-	-	-	0	4.5	-	1.78	-	209	0.00	F5	69.50
Seon et al (2014)	12	0	-	-	-	-	0	2	-	1.25	-	15	0.00	F5	88
Shen et al (2017)	13417	710	-	-	-	-	0	1	-	-	1.30	94040	0.76	F5	89
Shin et al (2006)	86	1	2	0	0	0	2	4 years after treatment start	-	3.83	-	330	0.30	F5	183
Slutkin et al (1988)	197	4	4	11	54	16	85	1	-	-	-	153	2.62	F5	9.3
Sonnenberg et al (2001)	326	65	-	-	-	-	0	31-Dec- 1998	629	2.09	-	629	10.33	F5	216
Spagnolo et al (1982)	49	0	4	-	-	5	9	2	-	-	-	89	0.00	F5	10.9
Sun et al (2017)	234	69	-	-	-	-	0	9	-	-	5.7	1971	3.50	F5	71.10
Suryanto et al (2008)	344	12	29	-	-	143	172	-	815		4.30	815	1.47	F5	363.00
Swaminathan et al (2008)	31	12	7	-	-	-	7	2	-	-	-	43	27.91	F5	289
Thomas et al (2005)	534	62	8	16	-	7	31	1.5	-	-	-	732	8.48	F5	289.00
Thomas et al (2019)	455	20	21	-	-	40	61	2	623	1.50	-	623	3.21	F5	211
Van der Heijden et al (2018)	3004	228	-	-	-	-	0	31-Dec-2013	-	3.00	-	9012	2.53	F5	963

Van Deun et al (2006)	15436	317	-	-	-	-	0	2	-	-	-	30555	1.04	F5	221.00
Van Deun et al (2010)	335	3	12	12	-	0	24	2	-	-	-	643	0.47	F3	221
Velayutham et al (2018)	1210	158	-	-	-	102	102	1	-	-	-	1244	12.70	F4	211
Vree et al (2007)	304.00	21	19	17	10	14	60	-	-	1.62	0.67	492	4.27	F5	27.90
Wang et al (2015)	508	18	-	-	-	-	0	2	860	-	-	860	2.09	F5	65.00
Westerlund et al (2015)	710	58	-	-	-	67	67	10	-	7.70	-	6632	0.87	F1	122
Wu et al (2015)	196	7	-	-	-	-	0	5	-	-	-	963	0.73	F1	27.90
Xia et al (2014)	935	31	-	-	-	-	-	4.0	-	-	-	3678	0.84	F5	67.00
Yen et al (2014)	5567	84	914	-	-	-	914	6	17166	-	-	17166	0.49	F1	86.00
Yoshiyama et al (2010)	170	5	3	31	-	15	49	1.	-	-	-	191	2.62	F5	163.00
Yoshiyama et al (2014)	168	3	4	-	-	-	4	-	-	4.40	1.10	739	0.41	F5	36.00
Zhdanov et al (2017)	3515	37	-	-	-	-	0	31/Dec/ 2011	23805	-	2.60	23805	0.16	F5	7.60
Anaam et al (2019)	814	71	28			35	63	5				3735.00	1.90	F5	48.00
Anh et al (2020)	79	0					0	2				158.00	0.00	F5	188.00
Ciza et al (2020)	209	1					0	2		1.07	0.5	224.68	0.45	F4	111.00
Decro et al (2020)	773	9						2				1537.00	0.59	F5	221.00
Lee et al (2020)	60	3					0	1		1.32	3.14	79.00	3.80	F4	146.00
Liu et al (2020)	4043	275					0	3				11716.50	2.35	F5	67.00
Malherbe et al (2020)	88	12				NO	0	2				164.00	7.32	F5	147.00
Mathur et al (2020)	187	7	15				15	2			1.09	352.63	1.99	F4	204.00
Park et al (2019)	35	1	1				1	2		3.47		121.33	0.82	F2	99.00
Peetluk et al (2019)	517	5					0	1.5				771.75	0.65	F5	43.00
Piubello et al (2020)	211	5	7			20	27	1			0.20	193.51	2.58	F4	105.00
Schwœbel et al (2020)	823	15	51			205	256	2		1.32	0.69	1132.08	1.33	F3	183.78
Zheng et al (2020)	35	10	4			2	6	5			2	130.00	7.69	F4	70.00
Bhatt et al (2017)	93	2										207.70	0.96	F1	244.00

*Formulas detailed in Appendix 3

Table S2: Proportion of relapses and reinfections in cohort studies, clinical trials and TB program database studies

Author	Genotyping molecular technique *	Recurrences	Recurrences with fingerprint results N (%)	Relapse N (%)	Reinfection N (%)	Background incidence per 100,000 pop**	Follow up period in years	HIV-prevalence
Clinical trials								
Conradie et al (2020)	WGS	2	1 (50)	1 (100)	0 (0)	146	0.49	19.3
El-Sadr et al (1998)	RFLP	2	1 (50)	1(100)	0	9.2	> 2	0.4
Jasmer Lorna et al (2004)	RFLP, Polymorphic guanine-cytosine–rich sequence–based RFLP analysis	81	75 (93)	72 (96)	3 (4)	6.7	2	0.4
Maug et al (2020)	Spoligotyping, MIRU VNTR, Deeplex MycTB	5	4 (80)	1 (25)	3 (75)	221	1	<1
Merle et al (2014)	MIRU VNTR	148	77 (52)	61 (79)	16 (21)	820	2	>1
Cohort studies								
Aung et al (2014)	Spoligotyping, MIRU VNTR	6	6 (100)	4(66)	2(33)	221	>2	<0.5
Charalambous et al (2008)	RFLP	42	16 (38)	5 (31)	11 (67)	585	1.02	14.65
Crampin et al (2010)	RFLP, Spoligotyping	53	39 (74)	26 (67)	13 (33)	392	10.75	14
Dale et al (2017)	MIRU VNTR	20	11 (55)	9 (82)	2 (18)	6.5	5.7	0.1
Decroo et al (2020)	Spoligotyping, MIRU VNTR, SNP genotyping	8	7 (87)	4 (57)	3 (43)	228	1.5	0.3
Guerra-Assunção et al (2015)	RFLP, Spoligotyping, WGS	139	75 (54)	55 (73)	20 (27)	397	2	14
Hawken et al (1993)	RFLP	11	3 (27)	2 (67)	1 (33)	72.3	1.25	5.5
Hesseling et al (2010)	RFLP	22	18 (82)	12 (67)	6 (33)	841	2	12.7
Huyen et al (2013)	Spoligotyping	35	35 (100)	23 (66)	12 (34)	172	1.5	0.4
Jimenez Corona et al (2013)	RFLP, Spoligotyping	74	38 (51)	31 (82)	7 (18)	21	5.14	0.3
Johnson et al (2000)	RFLP	4	4 (100)	0	4 (100)	117	2	9.5
Johnson et al (2003)	RFLP	2	2 (100)	0	2 (100)	248	6	9.5
Liu et al (2020)	MIRU VNTR	275	58 (21)	18 (31)	40 (69)	67.00	3	<0.1
Luzze et al (2013)	RFLP	171	98 (57)	80 (82)	18 (18)	400	1.24	6.5
Marx et al (2014) / Dippenar et al (2019)	RFLP. / WGS	203	130(64)	39(30)	91(70)	746	>2	14

Vega V, *et al. Thorax* 2021; 76:494–502. doi: 10.1136/thoraxjnl-2020-215449

Nahid et al (2007)	RFLP	16	11 (69)	11 (100)	0 (0)	8.7	1	0.4
Narayanan et al (2010)	RFLP, Spoligotyping, MIRU VNTR	74	48(65)	24(50)	24(50)	285	>2	0.1
Nettles et al (2004)	RFLP	14	9 (64)	9 (100)	0 (0)	7.9	1	0.4
Pettit et al (2011)	RFLP, Spoligotyping, MIRU VNTR	20	15 (75)	12 (80)	3 (20)	5.1	1	0.4
Piubello et al (2020)	No specified	5	5 (100)	1 (20)	4 (80)	105	0.92	0.3
Schwœbel et al (2020)	WGS, Spoligotyping	15	3 (20)	1 (33)	2 (66)	183	2	1.1
Shen et al (2017)	MIRU VNTR	710	141 (20)	82 (58)	59 (42)	89	1	0.1
Sonnenberg et al (2001)	RFLP	65	39 (60)	25 (64)	14 (36)	216	2.09	7.1
Van Deun et al (2004)	RFLP	2	2 (100)	1 (50)	1 (50)	52.9	2	<1
Van Deun et al (2010)	Spoligotyping	3	3 (100)	1 (33)	2 (66)	221	2	<0.5
Velayutham et al (2018)	MIRU VNTR	123	60 (48)	56 (93)	4 (7)	211	1	<0.5
TB program databases								
Bandera et al (2001)	RFLP, Spoligotyping	32	32 (60)	27 (84)	5 (16)	17.5	5	0.2
Cacho et al (2007)	RFLP, Spoligotyping, MIRU VNTR	8	8 (100)	7 (88)	1 (13)	25.7	6	0.4
Caminero et al (2001)	RFLP	11	8 (73)	2 (25)	6 (75)	22	5	0.4
Das et al (1993)	RFLP	42	42 (100)	37 (88)	5 (12)	109.3	2	0.2
Das et al (1995)	RFLP	62	62 (100)	22 (35)	40 (65)	130.7	3	0.2
Dobler et al (2009)	RFLP, Spoligotyping, MIRU VNTR	15	15 (100)	11 (73)	4 (27)	6.3	12	0.1
El Sahly et al (2004)	RFLP, Spoligotyping, genotyping method Not specified	100	25 (25)	19 (76)	6 (24)	2.9	5	0.4
Folkvardsen et al (2020)	WGS	32	13	9	4	8.3	22	0.1
Lourenço et al (2000)	RFLP, Polymorphic guanine-cytosine–rich sequence–based RFLP analysis , DRE-PCR	12	12 (100)	9 (75)	3 (25)	55.9	4	0.3
Parvaresh et al (2018)	MIRU VNTR, WGS	18	15(83)	13(87)	2(13)	6.3	6	0.1
Quy et al (2002) / Lan et al (2003)	RFLP	168	50 (30)	39 (78)	11 (22)	68	2	0.2
Rosser et al (2018)	MIRU VNTR	82	19(23)	16(84)	3(16)	13	20	0.16
Schiroli et al (2015)	Spoligotyping, MIRU VNTR	83	83 (100)	64 (77)	19 (23)	8.6	15	0.3

Shamputa et al (2007)	RFLP, Spoligotyping, MIRU VNTR	35	35 (100)	30 (86)	5 (14)	221	7	<1
Shen et al (2006)	RFLP, MIRU VNTR	202	52 (26)	20 (39)	32 (62)	102	5	0.1
Umubyeyi et al (2007)	Spoligotyping, MIRU VNTR	13	13 (100)	8 (62)	4 (31)	92	3	3.9
Van Rie et al (1999)	RFLP	48	16 (33)	4 (25)	12 (75)	1000	6	15.9

*RFLP= IS6110-restriction fragment length polymorphism, MIRU VNTR= mycobacterial interspersed repetitive unit-variable number tandem repeat typing; WGS: Whole Genome Sequencing

**Estimated incidence of tuberculosis for all cases as estimated the World Health Organization and reported in the Global Tuberculosis Database[16]

Vega V, *et al. Thorax* 2021; 76:494–502. doi: 10.1136/thoraxjnl-2020-215449

Appendix 7 Quality Assessment

Table S3 Recurrent TB incidence rate: Quality Assessment according to the modified NewCastle Ottawa Scale

Title	Selection		Outcome			Score		Overall qualiy Rating
	Representativeness of the population	Ascertainment of exposure	Assessment of outcome	Length of follow up	Adequacy of follow-up of cohorts	Selection	Outcome	
Anaam et al (2012)	A	B	A	B	B	1	1	POOR
Anaam et al (2019)	A	A	B	A	B	2	2	FAIR
Anh et al (2020)	C	B	B	A	A	0	2	POOR
Aung et al (2014)	C	B	A	A	A	0	2	POOR
Banu et al (2012)	A	A	A	A	A	2	3	GOOD
Becerra et al (2010)	C	A	A	A	B	1	2	FAIR
Bechan et al (1997)	A	A	A	B	A	2	2	FAIR
Bhatt et al (2017)	B	B	A	A	A	1	2	FAIR
Cao et al (1988)	A	A	A	A	A	2	3	GOOD
Castelo et al (1989)	A	B	A	B	D	1	0	POOR
Chaisson et al (1996)	A	A	A	A	A	2	3	GOOD
Chang et al (2004)	A	A	B	A	A	2	2	FAIR
Charalambous et al (2008)	B	A	B	A	A	2	2	FAIR
Chaulet et al (1995)	A	A	A	A	B	2	3	GOOD
Chiang et al (2006)	C	A	A	A	A	1	2	FAIR
Chien et al (2014)	C	B	A	A	A	0	2	POOR
Choi et al (2014)	A	A	A	A	B	2	3	GOOD
Ciza et al (2020)	C	A	A	A	A	1	2	FAIR
Cohn et al (1990)	A	B	A	A	D	1	1	POOR
Connolly et al (1999)	A	A	A	B	A	2	2	FAIR

Conradie et al (2020)	C	A	A	B	B	1	1	POOR
Cowie et al (1989)	B	A	B	A	A	2	2	FAIR
Crampin et al (2010)	A	A	B	A	A	2	2	FAIR
d'Arc et al (2008)	A	B	A	A	A	1	2	FAIR
Dale et al (2017)	A	B	A	B	A	1	1	POOR
Dangisso et al (2018)	B	B	A	A	A	1	2	FAIR
Datiko et al (2009)	A	A	A	A	A	2	3	GOOD
Decro et al (2020)	C	B	A	A	A	0	2	POOR
Dobler et al (2009)	A	B	A	B	A	1	1	POOR
Dornelles et al (2007)	A	A	A	A	A	2	3	GOOD
Dutt et al (1984)	A	A	A	A	A	2	3	GOOD
Dutt et al (1990)	A	A	A	A	A	2	3	GOOD
East African/BMRC (1980)	A	A	B	A	B	2	2	FAIR
East African/BMRC (1981)	A	A	A	B	B	2	2	FAIR
Escudero et al (2006)	C	A	A	A	A	1	2	FAIR
Fitzgerald et al (2000)	A	A	B	A	A	2	2	FAIR
Fox et al (2018)	A	B	A	A	A	1	2	FAIR
Garcia Martinez et al (1996)	A	A	A	A	B	2	3	GOOD
Gelmanova et al (2015)	C	B	A	A	B	0	2	POOR
Gengiah et al (2014)	C	B	A	A	A	0	2	POOR
Glynn et al (2010)	B	B	B	A	A	1	2	FAIR
Gonzalez-Montaner et al (1994)	A	A	A	A	C	2	2	FAIR
Gopalan et al (2018)	C	A	A	B	B	1	1	POOR
Guerra-Assunção et al (2015)	A	B	A	A	B	1	2	FAIR
Guglielmetti et al (2016)	C	B	A	A	C	0	1	POOR

Hang et al (2015)	A	A	A	B	B	2	2	FAIR
Hawken et al (1993)	C	A	A	A	A	1	2	FAIR
He et al (2010)	C	B	A	A	B	0	2	POOR
Hesseling et al (2010)	B	B	A	A	B	1	2	FAIR
Hong et al (1988)	C	A	A	A	C	1	1	POOR
Hong Kong Chest Service (1982)	A	A	A	B	B	2	2	FAIR
Hong Kong Chest Service/BMRC (1991)	A	A	A	A	B	2	3	GOOD
Houben et al (2012)	C	B	A	A	B	0	2	POOR
Huyen et al (2013)	A	A	A	B	B	2	2	FAIR
Jasmer et al (2004)	A	B	A	B	B	1	1	POOR
Jasmer Lorna et al (2004)	A	B	A	A	A	1	2	FAIR
Jawahar et al (2013)	A	A	B	A	A	2	2	FAIR
Jimenez Corona et al (2013)	A	B	A	A	A	1	2	FAIR
Jo et al (2014)	A	B	B	B	A	1	1	POOR
Johnson et al (2000)	A	A	A	A	A	2	3	GOOD
Johnson et al (2003)	A	B	A	B	A	1	1	POOR
Johnson et al (2009)	A	B	B	A	B	1	2	FAIR
Karagaoz et al (2009)	C	A	A	A	B	1	2	FAIR
Kassim et al (1995)	B	A	A	B	A	2	2	FAIR
Kennedy et al (1996)	A	B	B	B	A	1	1	POOR
Kenyan/Zambian/BMRC (1989)	A	A	A	A	B	2	3	GOOD
Kim et al (2017)	A	B	A	B	D	1	0	POOR
Kohno et al (1992)	A	A	A	A	B	2	3	GOOD
Kuaban et al (2015)	C	B	A	B	B	0	1	POOR

Lawal et al (2019	A	B	A	B	A	1	1	POOR
Lee et al (2011)	C	B	B	A	A	0	2	POOR
Lee et al (2012)	C	A	A	A	A	1	2	FAIR
Lee et al (2014)	C	B	A	B	A	0	1	POOR
Lee et al (2015)	C	B	A	B	A	0	1	POOR
Lee et al (2020)	C	B	A	B	A	0	1	POOR
Liu et al (2020)	A	A	B	A	A	2	2	FAIR
Luzze et al (2013)	B	A	A	B	A	2	2	FAIR
Ma et al (2018)	C	B	A	A	A	0	2	POOR
Madras/BMRC (1989)	C	B	A	A	B	0	2	POOR
Malherbe et al (2020)	A	A	A	A	D	2	2	FAIR
Mathur et al (2020)	A	A	B	A	A	2	2	FAIR
Maug et al (2020)	A	B	A	B	B	1	1	POOR
McGreevy et al (2012)	C	B	A	A	B	0	2	POOR
Merle et al (2014)	A	A	A	A	B	2	3	GOOD
Migliori et al (2002)	C	A	B	B	A	1	1	POOR
Mohanty et al (1993)	A	A	A	A	A	2	3	GOOD
Moreno-Martinez et al (2007)	A	A	A	B	A	2	2	FAIR
Nahid et al (2007)	C	A	A	A	C	1	1	POOR
narayanan et al (2007) trial	A	A	A	A	A	2	3	GOOD
Nettles et al (2004)	A	A	A	B	A	2	2	FAIR
Nolan et al (2002)	C	C	B	A	D	0	1	POOR
Palmero et al (2004)	C	A	A	B	A	1	1	POOR
Park et al (2019)	C	B	B	A	A	0	2	POOR
Parthasarathy et al (1991)	A	A	A	B	A	2	2	FAIR

Peetluk et al (2019)	A	B	B	B	A	1	1	POOR
Perez-Guzman et al (2002)	C	A	A	A	C	1	1	POOR
Perriens et al (1991)	A	A	A	B	B	2	2	FAIR
Perriens et al (1995)	A	A	A	B	C	2	1	POOR
Pettit et al (2011)	A	A	A	A	A	2	3	GOOD
Piubello et al (2014)	C	B	A	A	A	0	2	POOR
Piubello et al (2020)	C	B	A	B	B	0	1	POOR
Prasad et al (2004)	C	A	A	B	B	1	1	POOR
Prasad et al (2008)	A	B	A	B	A	1	1	POOR
Pulido et al (1997)	C	A	A	A	A	1	2	FAIR
Reis et al (1990)	C	A	A	A	A	1	2	FAIR
Schwœbel et al (2020)	C	B	A	A	C	0	1	POOR
Seon et al (2014)	B	B	A	A	A	1	2	FAIR
Shen et al (2017)	A	B	A	A	A	1	2	FAIR
Shin et al (2006)	C	B	A	A	A	0	2	POOR
Singapore/BMRC (1988)	A	A	B	A	B	2	2	FAIR
Singapore/BMRC (1991)	A	A	A	B	A	2	2	FAIR
Slutkin et al (1988)	A	B	A	B	B	1	1	POOR
Snider et al (1984)	A	A	A	A	D	2	2	FAIR
Sonnenberg et al (2001)	C	A	A	A	A	1	2	FAIR
Spagnolo et al (1982)	A	B	A	A	B	1	2	FAIR
Su et al (2001)	A	B	B	A	D	1	1	POOR
Sun et al (2017)	C	B	A	A	A	0	2	POOR
Suryanto et al (2008)	A	A	A	A	C	2	2	FAIR
Swai et al (1988)	C	A	A	A	B	1	2	FAIR

Swaminathan et al (2008)	C	A	B	A	A	1	2	FAIR
Tam et al (2002)	A	C	A	A	B	1	2	FAIR
Tanzania/BMRC (1985)	A	A	A	A	B	2	3	GOOD
Teo et al (1999)	A	B	A	A	B	1	2	FAIR
Thomas et al (2005)	A	A	A	B	B	2	2	FAIR
Thomas et al (2019)	A	A	B	A	B	2	2	FAIR
Tuberculosis Research Centre (1981)	A	A	A	A	A	2	3	GOOD
Tuberculosis Research Centre (1997)	A	A	A	A	B	2	3	GOOD
Van der Heijden et al (2018)	A	A	A	A	A	2	3	GOOD
Van Deun et al (2006)	A	B	A	A	A	1	2	FAIR
Van Deun et al (2010)	C	B	A	A	A	0	2	POOR
Velayutham et al (2018)	A	A	A	B	B	2	2	FAIR
Velayutham et al (2020)	A	A	B	A	A	2	2	FAIR
Vree et al (2007)	A	B	A	B	B	1	1	POOR
Wang et al (2015)	C	B	A	A	A	0	2	POOR
Westerlund et al (2015)	A	A	A	A	B	2	3	GOOD
Wu et al (2016)	A	B	A	B	A	1	1	POOR
Wu et al (2015)	A	B	A	A	A	1	2	FAIR
Xia et al (2014)	A	B	B	A	A	1	2	FAIR
Yan et al (2018)	C	B	B	A	C	0	1	POOR
Yen et al (2014)	A	B	B	A	A	1	2	FAIR
Yoshiyama et al (2010)	C	A	A	B	B	1	1	POOR
Yoshiyama et al (2014)	C	A	A	A	A	1	2	FAIR

Zhdanov et al (2017)	A	B	A	A	A	1	2	FAIR
Zheng et al (2020)	A	B	B	A	B	1	2	FAIR
Zierski et al (1981)	A	A	A	A	B	2	3	GOOD

*Each item received a maximum of one star according scale shown in Appendix 07. Score quality rating based on total number of stars received: Good quality: 2 in selection domain AND 3 in outcome domain. Fair quality: 1 star in selection domain OR 2 stars in outcome domain. Poor quality: If 0 stars in selection criteria OR 0-1 stars in outcome criteria

Table S4: Proportion of relapses and reinfections: Quality Assessment according to the modified NewCastle Ottawa Scale

Title	Selection	Outcome	Selection	Outcome	Selection	Scores		Overall Qualiy Rating
	Representativeness of population	Ascertainment of exposure	Assessment of outcome	Length of follow up	Lost to genotyping	Selection	Outcome	
Aung et al (2014)	C	B	A	A	A	0	3	POOR
Bandera et al (2001)	A	A	B	A	A	2	3	GOOD
Cacho et al (2007)	B	A	A	A	A	2	3	GOOD
Caminero et al (2001)	A	A	C	A	B	2	1	POOR
Charalambous et al (2008)	B	A	C	B	B	2	0	POOR
Conradie et al (2020)	C	A	A	B	B	1	1	POOR
Crampin et al (2010)	A	A	B	A	B	2	2	FAIR
Dale et al (2017)	A	B	A	A	B	1	2	FAIR
Das et al (1993)	C	A	C	A	A	1	2	FAIR
Das et al (1995)	B	A	C	A	A	2	2	FAIR
Decro et al (2020)	C	B	A	B	B	0	1	POOR
Dobler et al (2009)	A	B	A	A	A	1	3	FAIR
El Sahly et al (2004)	B	A	B	A	B	2	2	FAIR
El-Sadr et al (1998)	B	B	C	A	B	1	1	POOR
Folkvardsen et al (2020)	B	A	A	A	B	2	2	FAIR
Guerra-Assunção et al (2015)	A	B	A	A	B	1	2	FAIR
Hawken et al (1993)	C	A	C	B	B	1	0	POOR
Hesseling et al (2010)	B	B	C	A	B	1	1	POOR
Huyen et al (2013)	A	A	C	B	A	2	1	POOR
Jasmer Lorna et al (2004)	A	B	A	A	A	1	3	FAIR

Vega V, *et al. Thorax* 2021; 76:494–502. doi: 10.1136/thoraxjnl-2020-215449

Jimenez Corona et al (2013)	A	B	B	A	B	1	2	FAIR
Johnson et al (2000)	A	A	C	A	B	2	1	POOR
Johnson et al (2003)	A	B	C	A	A	1	2	FAIR
Liu et al (2020)	A	A	A	A	B	2	2	FAIR
Lourenço et al (2000)	C	B	B	A	A	0	3	POOR
Luzze et al (2013)	A	A	C	B	B	2	0	POOR
Marx et al (2014) / Dippenar et al (2019)	B	A	A	A	B	2	2	FAIR
Maug et al (2020)	A	B	A	B	B	1	1	POOR
Merle et al (2014)	A	A	A	A	B	2	2	FAIR
Nahid et al (2007)	C	A	C	B	B	1	0	POOR
Narayanan et al (2010)	A	A	A	A	B	2	2	FAIR
Nettles et al (2004)	A	A	C	B	B	2	0	POOR
Parvaresh et al (2018)	B	A	A	A	B	2	2	FAIR
Pettit et al (2011)	A	A	A	B	B	2	1	POOR
Piubello et al (2020)	C	B	D	B	A	0	1	POOR
Quy et al (2002) / Nguyen et al (2003)	B	A	C	A	B	2	1	POOR
Rosser et al (2018)	B	A	A	A	B	2	2	FAIR
Schiroli et al (2015)	A	A	A	A	A	2	3	GOOD
Schwœbel et al (2020)	C	B	A	A	B	0	2	POOR
Shamputa et al (2007)	A	B	A	A	A	1	3	FAIR
Shen et al (2006)	A	B	A	A	B	1	2	FAIR
Shen et al (2017)	A	B	A	A	B	1	2	FAIR
Sonnenberg et al (2001)	C	A	C	A	B	1	1	POOR
Umubyeyi et al (2007)	A	A	A	A	A	2	3	GOOD

Van Deun et al (2004)	B	B	C	A	A	1	2	FAIR
Van Deun et al (2010)	C	B	C	A	A	0	2	POOR
VanRie et al (1999)	A	B	C	A	B	1	1	POOR
Velayutham et al (2018)	A	A	A	B	B	2	1	POOR

*Each item received a maximum of one star according scale shown in Appendix 07. Score quality rating based on total number of stars received: Good quality: 2 in selection AND 3 in outcome. Fair quality: 1 star in selection OR 2 stars in outcome. Poor quality: 0 stars in selection OR 0-1 stars in outcome

Appendix 8 Supplementary figures

Figure S1 Recurrent TB incidence rate by background TB incidence level



Figure S2 Recurrent TB incidence rate by type of follow up



Figure S3 Forest plot of the recurrent TB incidence rate by study design



Figure S4 Forest plot of the recurrent TB incidence rate by TB drug regimen



Figure S5 Forest plot of the recurrent TB incidence rate by background HIV prevalence level



Figure S6 Forest plot of the recurrent TB incidence rate by study sample size



Figure S7 Forest plot of the recurrent TB incidence rate by study quality



Figure S8 Forest plot of the recurrent TB incidence rate by planned follow-up time



Figure S9 Funnel plot Recurrent TB incidence rate



Figure S10 Forest plot of the proportion of reinfections among recurrent TB episodes by background TB incidence



Figure S11 Forest plot of the proportion of reinfections among recurrent TB episodes by background HIV prevalence level



Figure S12 Forest plot of the proportion of reinfections among recurrent TB episodes by study design



Figure S13 Forest plot of the proportion of reinfections among recurrent TB episodes by length of follow-up/observation period



Figure S14 Forest plot of the proportion of reinfections among recurrent TB episodes by the proportion of episodes with DNA fingerprinting availability



Figure S15 Forest plot of the proportion of reinfections among recurrent TB episodes by molecular method used



Figure S16 Forest plot of the proportion of reinfections among recurrent TB episodes by study sample size



Figure S17 Forest plot of the proportion of reinfections among recurrent TB episodes by study quality



Figure S18 Funnel plot Proportion of reinfections



Appendix 9 References of included studies

1 Anaam MS, Alrasheedy AA, Alsahali S, *et al.* Rate and risk factors of recurrent tuberculosis in Yemen: a 5-year prospective study. *Infect Dis (London, England)* 2020;**52**:161–9. doi:10.1080/23744235.2019.1690162

2 Anaam MS, Ibrahim MIM, Al Serouri AW, Bassili A, Aldobhani A. A nested case-control study on relapse predictors among tuberculosis patients treated in Yemen's NTCP. *Public Health Action* 2012; **2**: 168–73.

3 Anh LTN, M V Kumar A, Ramaswamy G, *et al.* High Levels of Treatment Success and Zero Relapse in Multidrug-Resistant Tuberculosis Patients Receiving a Levofloxacin-Based Shorter Treatment Regimen in Vietnam. *Trop Med Infect Dis* 2020;**5**. doi:10.3390/tropicalmed5010043

4 Aung KJM, Declercq E, Ali MA, *et al.* Extension of the intensive phase reduces relapse but not failure in a regimen with rifampicin throughout. *Int J Tuberc Lung Dis* 2012; **16**: 455–61.

5 Aung KJM, Van Deun A, Declercq E, *et al.* Successful '9-month Bangladesh regimen' for multidrug-resistant tuberculosis among over 500 consecutive patients. *Int J Tuberc Lung Dis* 2014; **18**: 1180–7.

6 Babu Swai O, Aluoch JA, Githui WA, *et al.* Controlled clinical trial of a regimen of two durations for the treatment of isoniazid resistant pulmonary tuberculosis. *Tubercle* 1988;**69**:5–14. doi:10.1016/0041-3879(88)90035-9

7 Balasubramanian R, Sivasubramanian S, Vijayan VK, *et al.* Five year results of a 3-month and two 5-month regimens for the treatment of sputum-positive pulmonary tuberculosis in South India. *Tubercle* 1990; **71**: 253–8.

8 Banda H, Kang'ombe C, Harries AD, *et al.* Mortality rates and recurrent rates of tuberculosis in patients with smear-negative pulmonary tuberculosis and tuberculous pleural effusion who have completed treatment. *Int J Tuberc Lung Dis* 2000; **4**: 968–74.

9 Bandera A, Gori A, Catozzi L, *et al.* Molecular epidemiology study of exogenous reinfection in an area with a low incidence of tuberculosis. *J Clin Microbiol* 2001; **39**: 2213–8.

10 Banu Rekha V V, Rajaram K, Kripasankar AS, *et al.* Efficacy of the 6-month thrice-weekly regimen in the treatment of new sputum smear-positive pulmonary tuberculosis under clinical trial conditions. *Natl Med J India* 2012;**25**:196–200.NS -

11 Becerra MC, Appleton SC, Franke MF, *et al.* Recurrence after treatment for pulmonary multidrug-resistant tuberculosis. *Clin Infect Dis* 2010; **51**: 709–11.

12 Bechan S, Connolly C, Short GM, *et al.* Directly observed therapy in urban South Africa for tuberculosis given twice weekly in the workplace. *Trans R Soc Trop Med Hyg* 1997;**91**:704–7.NS -

13 Bhatt AN, Tharyan P, Michael JS, *et al.* Treatment outcomes with daily self-administered treatment and thrice-weekly directly-observed treatment in two cohorts of newly-diagnosed, sputum-positive adults with pulmonary tuberculosis. *Indian J Tuberc* 2020;**67**:105–11. doi:10.1016/j.ijtb.2017.05.012

14 Cacho J, Perez Meixeira A, Cano I, *et al.* Recurrent tuberculosis from 1992 to 2004 in a metropolitan area. *Eur Respir J* 2007; **30**: 333–7.

15 Caminero JA, Pena MJ, Campos-Herrero MI, *et al.* Exogenous reinfection with tuberculosis on a European island with a moderate incidence of disease. *Am J Respir Crit Care Med* 2001; **163**: 717–20.

16 Cao JP, Zhang LY, Zhu JQ, Chin DP. Two-year follow-up of directly-observed intermittent regimens for smear-positive pulmonary tuberculosis in China. *Int J Tuberc Lung Dis* 1998; **2**: 36-4

17 Castelo A, Jardim JR, Goihman S, *et al.* Comparison of daily and twice-weekly regimens to treat pulmonary tuberculosis. *Lancet* 1989; **2**: 1173–6.

18 Chaisson RE, Clermont HC, Holt EA, *et al.* Six-Month Supervised Intermittent Tuberculosis Therapy in Haitian Patients With and Without HIV Infection. 1996; **154**: 1034–8.

19 Chang KC, Leung CC, Yew WW, Ho SC, Tam CM. A nested case-control study on treatment-related risk factors for early relapse of tuberculosis. *Am J Respir Crit Care Med* 2004; **170**: 1124–30.

20 Charalambous S, Grant AD, Moloi V, *et al.* Contribution of reinfection to recurrent tuberculosis in South African gold miners. *Int J Tuberc Lung Dis* 2008; **12**: 942–8.

21 Chaulet P, Boulahbal F. Essai clinique d'une combinaison en proportions fixes de trois medicaments dans le traitement de la tuberculose. Tuber Lung Dis 1995;76:407–12. doi:10.1016/0962-8479(95)90006-3

22 Chiang C-Y, Enarson DA, Yu M-C, *et al.* Outcome of pulmonary multidrug-resistant tuberculosis: a 6-yr follow-up study. *Eur Respir J* 2006; **28**: 980–5.

23 Chien JY, Chen YT, Wu SG, Lee JJ, Wang JY, Yu CJ. Treatment outcome of patients with isoniazid mono-resistant tuberculosis. *Clin Microbiol Infect* 2014; **21**: 1–10.

24 Choi H, Lee M, Chen RY, *et al.* Predictors of pulmonary tuberculosis treatment outcomes in South Korea: a prospective cohort study, 2005-2012. *BMC Infect Dis* 2014; **14**: 360.

25 Ciza F, Gils T, Sawadogo M, *et al.* Course of Adverse Events during Short Treatment Regimen in Patients with Rifampicin-Resistant Tuberculosis in Burundi. *J Clin Med* 2020;**9**. doi:10.3390/jcm9061873

26 Cohn DL, Catlin BJ, Peterson KL, Judson FN, Sbarbaro JA. A 62-Dose , 6-Month Therapy for Pulmonary and Extrapulmonary Tuberculosis. *Ann Inter Med* 1990; **112**: 407–15.

27 Connolly C, Reid A, Davies G, Sturm W, McAdam KP, Wilkinson D. Relapse and mortality among HIV-infected and uninfected patients with tuberculosis successfully treated with twice weekly directly observed therapy in rural South Africa. *AIDS* 1999; **13**: 1543–7.

28 Conradie F, Diacon AH, Ngubane N, *et al.* Treatment of Highly Drug-Resistant Pulmonary Tuberculosis. *N Engl J Med* 2020;**382**:893–902. doi:10.1056/NEJMoa1901814

29 Cowie RL, Langton ME, Becklake MR. Pulmonary tuberculosis in South African gold miners. *Am Rev Respir Dis* 1989; **139**: 1086–9.

30 Crampin AC, Mwaungulu JN, Mwaungulu FD, *et al.* Recurrent TB: relapse or reinfection? The effect of HIV in a general population cohort in Malawi. *AIDS* 2010; **24**: 417–26.

31 D'Arc L. Smoking increases the risk of relapse after successful tuberculosis treatment. *Int J Epidemiol* 2008; **37**: 841-51.

32 Da S, Ghan SL, Allen BW, Mitchison DA. Application of DNA fingerprinting with IS986 to sequential mycobacterial isolates obtained from pulmonary tuberculosis patients in Hong Kong before , during and after short-course chemotherapy. 1993; **74**: 47-51

33 Dale KD, Globan M, Tay EL, Trauer JM, Trevan PG, Denholm JT. Recurrence of tuberculosis in a low-incidence setting without directly observed treatment: Victoria, Australia, 2002-2014. *Int J Tuberc Lung Dis* 2017; **21**: 550–5.

34 Dangisso MH, Woldesemayat EM, Datiko DG, Lindtjorn B. Long-term outcome of smear-positive tuberculosis patients after initiation and completion of treatment: A ten-year retrospective cohort study. *PLoS One* 2018; **13**: e0193396.

35 Das S, Paramasivan CN, Lowrie DB, *et al.* IS6110 restriction fragment length polymorphism typing of clinical isolates of Mycobacterium tuberculosis from patients with pulmonary tuberculosis in Madras, south India. *Tuber Lung Dis* 1995; **76**: 550–4.

36 Datiko DG, Lindtjorn B. Tuberculosis recurrence in smear-positive patients cured under DOTS in southern Ethiopia: retrospective cohort study. *BMC Public Health* 2009; **9**: 348.

37 Decroo T, Maug AKJ, Hossain MA, *et al.* Injectables' key role in rifampicin-resistant tuberculosis shorter treatment regimen outcomes. *PLoS One* 2020;**15**:e0238016. doi:10.1371/journal.pone.0238016

38 Dippenaar A, De Vos M, Marx FM, *et al.* Whole genome sequencing provides additional insights into recurrent tuberculosis classified as endogenous reactivation by IS6110 DNA fingerprinting. *Infect Genet Evol* 2019;**75**:103948. doi:10.1016/j.meegid.2019.103948

39 Dobler CC, Crawford AB, Jeffs PJ, Gilbert GL, Marks GB. Recurrence of tuberculosis in a low-incidence setting. *Eur Respir J* 2009; **33**: 160–7.

40 Dutt A, Stead WW. Short-Course Chemotherapy for Tuberculosis with Mainly Twice-Weekly lsoniazid and Rifampin Community Physicians' Seven-Year Experience with Mainly Outpatients. *Am J Med* 1984; **77**: 233-43

41 Dutt AK, Moers D, Stead WW. Smear-negative, culture-positive pulmonary tuberculosis. Six-month chemotherapy with isoniazid and rifampin. *Am Rev Respir Dis* 1990;**141**:1232–5.

42 el Sahly HM El, Wright JA, Soini H, Bui TT, Escalante P. Recurrent tuberculosis in Houston, Texas: a population-based study. *Int J Tuberc Lung Dis* 2004; **8**: 333–40.

43 el-Sadr WM, Perlman DC, Matts JP, *et al.* Evaluation of an Intensive Intermittent-Induction Regimen and Duration of Short-Course Treatment for Human Immunodeficiency Virus – Related Pulmonary Tuberculosis. ry Beirn Community Programs for Clinical Research on AIDS (CPCRA) and the AIDS Clinical Trials Group (ACTG). *Clin Infect Dis* 1998; **26**: 1148–58.

44 Escudero E, Peña JM, Vázquez JJ, Ortega A. Multidrug-resistant tuberculosis without HIV infection: success with individualized therapy. *Int J Tuberc Lung Dis* 2006; **10**: 409–14.

45 Fitzgerald DW, Desvarieux M, Severe P, Johnson WD Jr, Pape JW. Effect of post-treatment isoniazid on prevention of recurrent tuberculosis in HIV-1-infected individuals: a randomised trial. *Lancet* 2000; **356**: 1470–4.

46 Folkvardsen DB, Norman A, Rasmussen EM, *et al.* Recurrent tuberculosis in patients infected with the predominant Mycobacterium tuberculosis outbreak strain in Denmark. New insights gained through whole genome sequencing. *Infect Genet Evol J Mol Epidemiol Evol Genet Infect Dis* 2020;**80**:104169. doi:10.1016/j.meegid.2020.104169

47 Fox GJ, Nguyen VN, Dinh NS, *et al.* Post-treatment Mortality Among Patients With Tuberculosis : A Prospective Cohort Study of 10 964 Patients in Vietnam. *Clin Infect Dis* 2018; **68**: 1–8.

48 Gelmanova IY, Ahmad Khan F, Becerra MC, *et al.* Low rates of recurrence after successful treatment of multidrug-resistant tuberculosis in Tomsk, Russia. *Int J Tuberc Lung Dis* 2015; **19**: 399–405.

49 Gengiah TN, Botha JH, Soowamber D, Naidoo K, Karim SSA. Original Article Low rifampicin concentrations in tuberculosis patients with HIV infection. *J Infect Dev Ctries* 2014; **8**: 987-93.

50 Glynn JR, Murray J, Bester A, Nelson G, Shearer S, Sonnenber P. High rates of recurrence in HIV-infected and HIV-uninfected patients with tuberculosis. *J Infect Dis* 2010; **201**: 704–11.

51 Gonzales Montaner D. Rifabutin for the treatment of newly-diagnosed pulmonary tuberculosis : a multinational , randomized , comparative study versus Rifampicin. *Tuber Lung Dis* 1994; **75**: 341-7.

52 Gopalan N, Santhanakrishnan RK, Palaniappan AN, et al. Daily vs Intermittent Antituberculosis Therapy for Pulmonary Tuberculosis in Patients With HIV A Randomized Clinical Trial. *JAMA Intern Med* 2018; **178**: 110029: 1–9.

53 Guerra-Assunção JA, Houben RMGJ, Crampin AC, *et al.* Recurrence due to Relapse or Reinfection With Mycobacterium tuberculosis : A Whole-Genome Sequencing Approach in a Large , Population- Based Cohort With a High HIV Infection Prevalence and Active Follow-up. *J Infect Dis* 2015; **211**: 1154-63.

54 Guglielmetti L, Jaspard M, Dû D Le, *et al.* Long-term outcome and safety of prolonged bedaquiline treatment for multidrug-resistant tuberculosis. *Eur Respir J* 2017. DOI:10.1183/13993003.01799-2016.

55 Hang NTL, Maeda S, Keicho N, *et al.* Sublineages of Mycobacterium tuberculosis Beijing genotype strains and unfavorable outcomes of anti-tuberculosis treatment. *Tuberculosis* 2015; **95**: 336–42.

56 Hawken M, Nunn P, Gatua S, *et al.* Increased recurrence of tuberculosis in HIV-1-infected patients in Kenya. *Lancet* 1993; **342**: 332–7.

57 He GX, Xie YG, Wang LX, *et al.* Follow-up of patients with multidrug resistant tuberculosis four years after standardized first-line drug treatment. *PLoS One* 2010; **5**: e10799.

58 Heijden YF Van Der, Karim F, Chinappa T, Mufamadi G, Zako L, Shepherd BE. Older age at first tuberculosis diagnosis is associated with tuberculosis recurrence in HIV-negative persons. 2018; **22**: 871–7.

59 Hesseling AC, Walzl G, Enarson DA, *et al.* Baseline sputum time to detection predicts month two culture conversion and relapse in non-HIV-infected patients. *Int J Tuberc Lung Dis* 2010; **14**: 560–70.

60 Hong YP, Kim SC, Chang SC, Kim SJ, Jin BW, Park CD. Comparison of a daily and three intermittent retreatment regimens for pulmonary tuberculosis administered under programme conditions. *Tubercle* 1988; **69**: 241–53.

61 Houben RMGJ, Glynn JR, Mboma S, *et al.* The impact of HIV and ART on recurrent tuberculosis in a sub-Saharan setting. *AIDS* 2012; **26**: 2233–9.

62 Huyen MNT, Buu TN, Tiemersma E, *et al.* Tuberculosis Relapse in Vietnam Is Signi fi cantly Associated With Mycobacterium tuberculosis Beijing Genotype Infections. J Infect Dis 2013; **207**. DOI:10.1093/infdis/jit048.

63 Jasmer RM, Boezeman L, Schwartzman K, *et al.* Recurrent tuberculosis in the United States and Canada: relapse or reinfection? *Am J Respir Crit Care Med* 2004; **170**: 1360–6.

64 Jasmer RM, Seaman CB, Gonzalez LC, Kawamura LM, Osmond DH, Daley CL. Tuberculosis treatment outcomes: Directly observed therapy compared with self-administered therapy. *Am J Respir Crit Care Med* 2004; **170**: 561–6.

65 Jawahar MS, Banurekha V V, Paramasivan CN, *et al.* Randomized clinical trial of thrice-weekly 4-month moxifloxacin or gatifloxacin containing regimens in the treatment of new sputum positive pulmonary tuberculosis patients. *PLoS One* 2013;**8**:e67030.

66 Jiménez-Corona ME, Cruz-hervert LP, García-garcía L, *et al.* Association of diabetes and tuberculosis : impact on treatment and post-treatment outcomes. *Thorax* 2013; **68**: 214–20.

67 Jo K, Yoo J, Hong Y, *et al.* ScienceDirect Risk factors for 1-year relapse of pulmonary tuberculosis treated with a 6-month daily regimen. *Respir Med* 2014; **108**: 654–9.

68 Johnson JL, Hadad DJ, Dietze R, *et al.* Shortening treatment in adults with noncavitary tuberculosis and 2-month culture conversion. *Am J Respir Crit Care Med* 2009; **180**: 558–63.

69 Johnson JL, Okwera A, Nsubuga P, *et al.* Efficacy of an unsupervised 8-month rifampicin-containing regimen for the treatment of pulmonary tuberculosis in HIV-infected adults. 2000; **4**: 1032–40.

70 Johnson JL, Ssekasanvu E, Okwera A, *et al.* Randomized trial of adjunctive interleukin-2 in adults with pulmonary tuberculosis. *Am J Respir Crit Care Med* 2003; **168**: 185–91.

71 Karagöz T, Moçİn ÖY, Pazarli P, *et al.* The treatment results of patients with multidrug resistant tuberculosis and factors affecting treatment outcome. *Tuberk Toraks* 2009; **57**: 383–92.

72 Kassim S, Sassan-Morokro M, Ackah A, *et al.* Two-year follow-up of persons with HIV-1- and HIV-2-associated pulmonary tuberculosis treated with short-course chemotherapy in West Africa. *AIDS* 1995; **9**: 1185–91.

73 Kennedy AN, Berger L, Curram J, *et al.* Randomized controlled trial of a drug regimen that includes ciprofloxacin for the treatment of pulmonary tuberculosis. *Clin Infect Dis* 1996;**22**:827–33.NS -

74 Kim S, Lee H, Park HY, *et al.* Outcomes of pulmonary tuberculosis in patients with discordant phenotypic isoniazid resistance testing. *Respir Med* 2017; **133**: 6–11.

75 Kohno S, Koga H, Kaku M, *et al.* Prospective comparative study of ofloxacin or ethambutol for the treatment of pulmonary tuberculosis. *Chest* 1992; **102**: 1815–8.

76 Kong H, Service C, Medical B. Controlled Trial of 2, 4, and 6 Months of Pyrazinamide in 6-Month, Three-Times-Weekly Regimens for Smear-positive Pulmonary Tuberculosis, Including an Assessment of a Combined Preparation of Isoniazid, Rifampin and pyrazinamide. Results at 30 months. Hong Kong Chest Service/British Medical Research Council. *Am Rev Respir Dis* 1990; **143:** 1–7.

77 Kuaban C, Noeske J, Rieder HL, *et al.* High effectiveness of a 12-month regimen for MDR-TB patients in Cameroon. *Int J Tuberc Lung Dis* 2015; **19**: 517–24.

78 Lan NTN, Lien HTK, Tung LB, *et al.* Mycobacterium tuberculosis Beijing Genotype and Risk for Treatment Failure and Relapse, Vietnam. *Emerg Infect Dis* 2003;**9**:1633–5. doi:10.3201/eid0912.030169

79 Lawal I, Fourie B, Mathebula M, *et al.* FDG-PET/CT as a non invasive biomarker for assessing adequacy of treatment and predicting relapse in patients treated for pulmonary tuberculosis. *J Nucl Med* 2019; DOI:10.2967/jnumed.119.233783.

80 Lee H, Jeong B-H, Park HY, *et al.* Treatment Outcomes with Fluoroquinolone-Containing Regimens for Isoniazid-Resistant Pulmonary Tuberculosis. *Antimicrob Agents Chemother* 2015;**60**:471–7. doi:10.1128/AAC.01377-15

81 Lee H, Sohn JW, Sim YS, *et al.* Outcomes of extended duration therapy for drug-susceptible cavitary pulmonary tuberculosis. *Ann Transl Med* 2020;**8**:346. doi:10.21037/atm.2020.02.104

82 Lee J, Lim H-J, Cho Y-J, *et al.* Recurrence after successful treatment among patients with multidrug-resistant tuberculosis. *Int J Tuberc Lung Dis* 2011; **15**: 1331–3.

83 Lee M, Lee J, Carroll MW, *et al.* Linezolid for treatment of chronic extensively drug-resistant tuberculosis. *N Engl J Med* 2012; **367**: 1508–18.

84 Lee P-H, Lin H-C, Huang AS-E, Wei S-H, Lai M-S, Lin H-H. Diabetes and risk of tuberculosis relapse: nationwide nested case-control study. *PLoS One* 2014; **9**: e92623.

85 Liu Y, Zhang XX, Yu JJ, *et al.* Tuberculosis relapse is more common than reinfection in Beijing, China. *Infect Dis (London, England)* 2020;:1–8. doi:10.1080/23744235.2020.1794027

86 Lourenço MCS, Grinsztejn B, Fandinho-Montes FCO, Da Silva MG, Saad MHF, Fonseca LS. Genotypic patterns of multiple isolates of M. tuberculosis from tuberculous HIV patients. *Trop Med Int Heal* 2000; **5**: 488–94.

87 Luzze H, Johnson DF, Dickman K, *et al.* Relapse more common than reinfection in recurrent tuberculosis 1 – 2 years post treatment in urban Uganda. *Int J Tuberc Lung Dis* 2013; **17**: 361–7.

88 Ma Y, Pang Y, Shu W, *et al.* Metformin reduces the relapse rate of tuberculosis patients with diabetes mellitus: experiences from 3-year follow-up. *Eur J Clin Microbiol Infect Dis* 2018; **37**: 1259–63.

89 Malherbe ST, Chen RY, Dupont P, *et al.* Quantitative 18F-FDG PET-CT scan characteristics correlate with tuberculosis treatment response. *EJNMMI Res* 2020;**10**:8. doi:10.1186/s13550-020-0591-9

90 Martinez FD, Hernandez HM. Relapse after short-course chemotherapy of patients with sputum smear-positive pulmonary tuberculosis under routine conditions with additional information on side effects and contact tracing. *Tuber Lung Dis* 1996; **77**: 425–8.

91 Marx FM, Dunbar R, Enarson DA, *et al.* The temporal dynamics of relapse and reinfection tuberculosis after successful treatment: a retrospective cohort study. *Clin Infect Dis* 2014; **58**: 1676–83.

92 Mathur N, Chatla C, Syed S, *et al.* Prospective 1-year follow-up study of all cured, new sputum smear positive tuberculosis patients under the Revised National Tuberculosis Control Program in Hyderabad, Telangana State, India. *Lung India* 2019;**36**:519–24. doi:10.4103/lungindia.lungindia_143_19

93 Maug AKJ, Hossain MA, Gumusboga M, *et al.* First-line tuberculosis treatment with double-dose rifampicin is well tolerated. *Int J Tuberc lung Dis Off J Int Union against Tuberc Lung Dis* 2020;**24**:499–505. doi:10.5588/ijtld.19.0063

94 McGreevy J. Outcomes of HIV-infected patients treated for recurrent tuberculosis with the standard retreatment regimen. *Int J Tuberc Lung Dis* 2012; **16**: 841–5.

95 Merle CS, Fielding K, Bah Sow O, *et al.* A Four-Month Gatifloxacin-Containing Regimen for Treating Tuberculosis. N Eng J Med 2014; 371: 1588-98

96 Migliori GB, Espinal M, Danilova ID, *et al.* Frequency of recurrence among MDR-TB cases 'successfully' treated with standardised short-course chemotherapy. *Int J Tuberc Lung Dis* 2002; **6**: 858–64.

97 Miles SH, Maat RB. A successful supervised outpatient short-course tuberculosis treatment program in an open refugee camp on the Thai-Cambodian border. *Am Rev Respir Dis* 1984;**130**:827–30. doi:10.1164/arrd.1984.130.5.827

98 Mohanty KC, Dhamgaye MD. Controlled Trial of Ciprofloxacin in Short-term Chemotherapy for Pulmonary Tuberculosis. *Chest* 1993, **104**: 1194-8.

99 Moosazadeh M, Bahrampour A, Nasehi M, *et al.* The incidence of recurrence of tuberculosis and its related factors in smear-positive pulmonary tuberculosis patients in Iran: A retrospective cohort study. *Lung India* 2015; **32**: 557–60.

100 Moreno-Martinez R. Incidencia de recaída y factores de riesgo asociados en pacientes con tuberculosis pulmonar. *Rev Med Inst Mex Segur Soc* 2007; **45**: 335–42.

101 Nahid P, Gonzalez LC, Rudoy I, *et al.* Treatment outcomes of patients with HIV and tuberculosis. *Am J Respir Crit Care Med* 2007; **175**: 1199–206.

102 Narayanan S, Swaminathan S, Supply P, *et al.* Impact of HIV infection on the recurrence of tuberculosis in South India. *J Infect Dis* 2010; **201**: 691–703.

103 Nettles RE, Mazo D, Alwood K, *et al.* Risk factors for relapse and acquired rifamycin resistance after directly observed tuberculosis treatment: a comparison by HIV serostatus and rifamycin use. *Clin Infect Dis* 2004; **38**: 731–6.

104 No authors listed. A Controlled Clinical Trial of 3- and 5-month regimens in the treatment of sputum-positive pulmonary tuberculosis in South India. Tuberculosis Research Centre, Madras, and National Tuberculosis Institute, Bangalore. *Am Rev Respir Dis* 1986; **134**: 27–33.

105 No authors listed. A controlled clinical trial of oral short-course regimens in the treatment of sputum-positive pulmonary tuberculosis. Tuberculosis Research Center. *Int J Tuberc Lung Dis* 1997; **1**: 509-17

106 No authors listed. A Controlled Trial of 3-Month, 4-Month, and 6-Month Regimens of Chemotherapy for Sputum-smear-negative Pulmonary Tuberculosis. Results at 5 years. Hong Kong Chest Service/Tuberculosis Research Centre, Madras/British Medical Research Council. *Am Rev Respir Dis* 1988; **139**: 871–6.

107 No authors listed. Assessment of a Daily Combined Preparation of Isoniazid , Rifampin , and Pyrazinamide in a Controlled Trial of Three 6-Month Regimens for Smear-positive Pulmonary Tuberculosis. *Am Rev Respir Dis* 1990; : 707–12.

108 No authors listed. Clinical trial of six-month and four-month regimens of chemotherapy in the treatment of pulmonary tuberculosis: the results up to 30 months. *Tubercle* 1981; **62**: 95–102.

109 No authors listed. Controlled clinical trial of 4 short-course regimens of chemotherapy (three 6-month and one 8-month) for pulmonary tuberculosis: Final report. *Tubercle* 1986; **67**: 5–15.

110 No authors listed. Controlled clinical trial of four short-course regimens of chemotherapy for two durations in the treatment of pulmonary tuberculosis. Second report. Third East African/British Medical Research Council Study. *Tubercle* 1980; **61**: 59–69.

111 No authors listed. Controlled Clinical Trial of Levamisole in Short-course Chemotherapy for Pulmonary Tuberculosis. *Am Rev Respir Dis* 1989; **140**: 990-5

112 No authors listed. Controlled Clinical Trial of Two 6-Month Regimens of Chemotherapy in the Treatment of Pulmonary Tuberculosis. Tanzania/British Medical Research Council study. *Am Rev Respir Dis* 1985; **131**: 727–31.

113 No authors listed. Controlled trial of 4 three-times-weekly regimens and a daily regimen all given for 6 months for pulmonary tubreculosis second reporrt: the results up to 24 months. Hong Kong Chest Service/British Medical Research Council. *Tubercle* 1982; **63**: 89–98.

114 No authors listed. Ethambutol plus isoniazid for the treatment of tuberculosis – a controlled trial of four. *Tubercle* 1981; **61**: 13–29.

115 No authors listed. Evaluation of a non-rifampicin continuation phase (6HE) following thrice-weekly intensive phase for the treatment of new sputum positive pulmonary tuberculosis. *Indian J Tuberc* 2007; **54**: 84-90

116 No authors listed. Five year Follow-Up of a Clinical Trial of Three 6-Month Regimens of Chemotherapy Given Intermittently in the Continuation Phase in the Treatment of Pulmonary Tuberculosis. *Am Rev Respir Dis*1988; **137**: 1147–50.

117 No authors listed. Report S. Controlled Clinical Trial of Five Short-Course (4-Month) Chemotherapy Regimens in Pulmonary Tuberculosis Second Report of the 4th Study. *Am Rev Respir Dis* 1980; **123**: 165–70.

118 Nolan CM, Goldberg S V. Treatment of isoniazid-resistant tuberculosis with isoniazid , rifampin , ethambutol , and pyrazinamide for 6 months. 2002; **6**: 952–8.

119 Ormerod LP, Horsfield N, Green RM. Tuberculosis treatment outcome monitoring : Blackburn 1988 – 2000 SUMMARY. 2002; **6**: 662–5.

120 Palmero DJ, Ambroggi M, Brea A, *et al.* Treatment and follow-up of HIV-negative multidrug-resistant tuberculosis patients in an infectious diseases reference hospital, Buenos Aires, Argentina. *Int J Tuberc Lung Dis* 2004; **8**: 778–84.

121 Park DW, Chung SJ, Yeo Y, *et al.* Therapeutic issues with, and long-term outcomes of, pulmonary mycobacterial tuberculosis treatment in patients with autoimmune rheumatic diseases. *J Thorac Dis* 2019;**11**:4573–82. doi:10.21037/jtd.2019.10.74

122 Parvaresh L, Crighton T, Martinez E, Bustamante A, Chen S, Sintchenko V. Recurrence of tuberculosis in a low-incidence setting: a retrospective cross-sectional study augmented by whole genome sequencing. *BMC Infect Dis* 2018; **18**: 265.

123 Peetluk LS, Rebeiro PF, Cordeiro-Santos M, *et al.* Lack of Weight Gain During the First 2 Months of Treatment and Human Immunodeficiency Virus Independently Predict Unsuccessful Treatment Outcomes in Tuberculosis. *J Infect Dis* 2020;**221**:1416–24. doi:10.1093/infdis/jiz595

124 Perez Guzman H. Results of a 12-month regimen for drug-resistant pulmonary tuberculosis. *Int J Tuberc Lung Dis* 2002; **6**: 1102–9.

125 Perriëns JH, Colebunders RL, Karahunga C, *et al.* Increased Mortality and Tuberculosis Treatment Failure Rate among Human Immunodeficiency Virus (HIV) Seropositive Compared with HIV Seronegative Patients with Pulmonary Tuberculosis Treated with " Standard " Chemotherapy in Kinshasa, Zaire. *Am Rev Respir Dis* 1991; **144**: 750-5

126 Perriëns JH, St Louis ME, Mukadi YB, *et al*. Pulmonary tuberculosis in HIV infected patients in Zaire, a Controlled Trial of Treatment for Either 6 or 12 Months. *N Eng J Med* 1995; **332**: 779–84.

127 Pettit AC, Kaltenbach LA, Maruri F, *et al.* Chronic lung disease and HIV infection are risk factors for recurrent tuberculosis in a low-incidence setting. *Int J Tuberc Lung Dis* 2011; **15**: 906–11.

128 Picon PD, Bassanesi SL, Caramori MLA, *et al.* Risk factors for recurrence of tuberculosis. *J Bras Pneumol* 2007; **33**: 572–8.

129 Piubello A, Harouna SH, Souleymane MB, *et al.* High cure rate with standardised short-course multidrug-resistant tuberculosis treatment in Niger: no relapses. *Int J Tuberc Lung Dis* 2014; **18**: 1188–94.

130 Piubello A, Souleymane MB, Hassane-Harouna S, *et al.* Management of multidrug-resistant tuberculosis with shorter treatment regimen in Niger: Nationwide programmatic achievements. *Respir Med* 2020;**161**:105844. doi:10.1016/j.rmed.2019.105844

131 Prasad R, Verma SK, Sahai S, Kumar S, Jain A, Prasad R. Efficacy and Safety of Kanamycin , Ethionamide , PAS and Cycloserine in Multidrug-

resistant Pulmonary Tuberculosis Patients. *Indian J Chest Dis Allied Sci* 2004; **226003**.

132 Prasad R, Verma SK, Shrivastava P, *et al.* A follow up study on revised national tuberculosis control programme (rntcp): results from a single centre study. *Lung India* 2008; **25**: 142–4.

133 Pulido F, Pena J, Rubio R, *et al*. Relapse of Tuberculosis After Treatment in Human Immunodeficiency Virus Infected Patients. *Arch Intern Med* 1997. **157**: 227-3.

134 Reis FJ, Bedran MBM, Moura JAR, Assis I, Rodrigues MESM. Six-Month Isoniazid-Rifampin Treatment for Pulmonary Tuberculosis in Children. *Am Rev Resp Dis* 1990; **142**: 1–4.

135 Rosser A, Richardson M, Wiselka MJ, *et al.* A nested case-control study of predictors for tuberculosis recurrence in a large UK Centre. *BMC Infect Dis* 2018; **18**: 94.

136 Schiroli C, Carugati M, Zanini F, *et al.* Exogenous reinfection of tuberculosis in a low-burden area. *Infection* 2015; **43**: 647–53.

137 Schwœbel V, Trébucq A, Kashongwe Z, *et al.* Outcomes of a nine-month regimen for rifampicin-resistant tuberculosis up to 24 months after treatment completion in nine African countries. *EClinicalMedicine* 2020;**20**:100268. doi:10.1016/j.eclinm.2020.100268

138 Seon HJ, Kim YI, Lim SC, Kim YH, Kwon YS. Clinical significance of residual lesions in chest computed tomography after anti-tuberculosis treatment. *Int J Tuberc Lung Dis* 2014; **18**: 341–6.

139 Shamputa IC, Van Deun A, Salim MAH, *et al.* Endogenous reactivation and true treatment failure as causes of recurrent tuberculosis in a high incidence setting with a low HIV infection. *Trop Med Int Health* 2007; **12**: 700–8.

140 Shen G, Xue Z, Shen X, Gui X, Shen M, Mei J. Tuberculosis and Exogenous. *Emerg Infect Dis* 2006; **12**: 11–3.

141 Shen X, Yang C, Wu J, *et al.* Recurrent tuberculosis in an urban area in China: Relapse or exogenous reinfection? *Tuberculosis* 2017; **103**: 97–104.

142 Shin SS, Furin JJ, Alcantara F, *et al.* Long-term follow-up for multidrug-resistant tuberculosis. *Emerg Infect Dis* 2006; **12**: 687–8.

143 Slutkin G, Schecter GF, Hopewell PC. The results of 9-month isoniazid-rifampin therapy for pulmonary tuberculosis under program conditions in San Francisco. *Am Rev Respir Dis* 1988;**138**:1622–4. doi:10.1164/ajrccm/138.6.1622

144 Snider DE, Gracyzk J, Bek E, Rogowski J. Supervised six-months treatment of newly diagnosed pulmonary tuberculosis using isoniazid, rifampin, and

pyrazinamide with and without streptomycin. *Am Rev Respir Dis* 1984; **130**: 1091–4.

145 Somner AR. Short-course chemotherapy in pulmonary tuberculosis. A controlled trial by the British Thoracic Association (third report). *Lancet* 1980; **1**: 1182–3.

146 Sonnenberg P, Murray J, Glynn JR, Shearer S, Kambashi B, Godfrey-Faussett P. HIV-1 and recurrence, relapse, and reinfection of tuberculosis after cure: a cohort study in South African mineworkers. *Lancet* 2001; **358**: 1687–93.

147 Spagnolo S V, Raver JM. Nine-month chemotherapy for pulmonary tuberculosis. *South Med J* 1982; **75**: 134-137,142.

148 Su WJ, Perng RP. Fixed-dose combination chemotherapy (Rifater/Rifinah) for active pulmonary tuberculosis in Taiwan: a two-year follow-up. *Int J Tuberc Lung Dis* 2002; **6**: 1029–32.

149 Sun Y, Harley D, Vally H, Sleigh A. Impact of Multidrug Resistance on Tuberculosis Recurrence and Long-Term Outcome in China. *PLoS One* 2017; **12**: e0168865.

150 Suryanto AA, van den Broek J, Hatta M, de Soldenhoff R, van der Werf MJ. Is there an increased risk of TB relapse in patients treated with fixed-dose combination drugs in Indonesia? *Int J Tuberc Lung Dis* 2008; **12**: 174–9.

151 Swaminathan S, Rajasekaran S, Venkatesan P, Kamakoti K, Trust C, Padmapriyadarsini C. Long term follow up of HIV-infected patients with tuberculosis treated with 6-month intermittent short course chemotherapy. Natl Med India 2007; **21**: 3-8

152 Tam CM, Chan SL, Kam KM, *et al.* Rifapentine and isoniazid in the continuation phase of a 6-month regimen. Final report at 5 years: prognostic value of various measures. *Int J Tuberc Lung Dis* 2002; **6**: 3–10.

153 Teo SK. Assessment of a combined preparation of isoniazid, rifampicin and pyrazinamide (Rifater) in the initial phase of chemotherapy in three 6-month regimens for smear-positive pulmonary tuberculosis: a five-year follow-up report. *Int J Tuberc Lung Dis* 1999;**3**:126–32.NS -

154 Thomas A, Gopi PG, Santha T, *et al.* Predictors of relapse among pulmonary tuberculosis patients treated in a DOTS programme in South India. *Int J Tuberc Lung Dis* 2005; **9**: 556–61.

155 Thomas BE, Thiruvengadam K, S R, *et al.* Smoking, alcohol use disorder and tuberculosis treatment outcomes: A dual co-morbidity burden that cannot be ignored. *PLoS One* 2019; **14**: e0220507.

156 Umubyeyi AN, Shamputa IC, Rigouts L, *et al.* Molecular investigation of recurrent tuberculosis in patients from Rwanda. *Int J Tuberc Lung Dis* 2007; **11**: 860–7.

157 Van Deun A, Aung KJ, Salim MA, *et al.* Extension of the intensive phase reduces unfavourable outcomes with the 8-month thioacetazone regimen. *Int J Tuberc Lung Dis* 2006; **10**: 1255–61.

158 Van Deun A, Maug AKJ, Salim MAH, *et al.* Short, highly effective, and inexpensive standardized treatment of multidrug-resistant tuberculosis. *Am J Respir Crit Care Med* 2010;**182**:684–92. doi:10.1164/rccm.201001-0077OC

159 Van Deun A, Salim MA, Das PK, Bastian I, Portaels F. Results of a standardised regimen for multidrug-resistant tuberculosis in Bangladesh. *Int J Tuberc Lung Dis* 2004; **8**: 560–7.

160 van Rie A, Warren R, Richardson M, *et al.* Exogenous reinfection as a cause of recurrent tuberculosis after curative treatment. *N Engl J Med* 1999; **341**: 1174–9.

161 Velayutham B, Chadha VK, Singla N, *et al.* Recurrence of tuberculosis among newly diagnosed sputum positive pulmonary tuberculosis patients treated under the Revised National Tuberculosis Control Programme, India: A multi-centric prospective study. *PLoS One* 2018; **13**: e0200150.

162 Velayutham B, Jawahar MS, Nair D, *et al.* 4-month moxifloxacin containing regimens in the treatment of patients with sputum-positive pulmonary tuberculosis in South India - a randomised clinical trial. *Trop Med Int Health* 2020;**25**:483–95. doi:10.1111/tmi.13371

163 Vieira AA, Leite DT, Adreoni S. Tuberculosis recurrence in a priority city in the state of Sao Paulo, Brazil. *J Bras Pneumol* 2017; **43**: 106–12.

164 Vree M, Huong NT, Duong BD, *et al.* Survival and relapse rate of tuberculosis patients who successfully completed treatment in Vietnam. *Int J Tuberc Lung Dis* 2007; **11**: 392–7.

165 Wang J-Y, Sun H-Y, Wang J-T, *et al.* Nine- to Twelve-Month Anti-Tuberculosis Treatment Is Associated with a Lower Recurrence Rate than 6-9-Month Treatment in Human Immunodeficiency Virus-Infected Patients: A Retrospective Population-Based Cohort Study in Taiwan. *PLoS One* 2015; **10**: e0144136.

166 Westerlund EE, Tovar MA, Lonnermark E, Montoya R, Evans CA. Tuberculosis-related knowledge is associated with patient outcomes in shantytown residents; results from a cohort study, Peru. *J Infect* 2015; **71**: 347–57.

167 Wu J-T, Chiu C-T, Wei Y-F, Lai Y-F. Comparison of the safety and efficacy of a fixed-dose combination regimen and separate formulations for pulmonary tuberculosis treatment. *Clinics (Sao Paulo)* 2015; **70**: 429–34.

168 Wu Z, Guo J, Huang Y, Cai E, Zhang X, Pan Q. Journal of Diabetes and Its Complications Diabetes mellitus in patients with pulmonary tuberculosis in an aging population in Shanghai , China : Prevalence , clinical characteristics and outcomes. *J Diabetes Complications* 2015; **30**: 237-41

169 Xia Y, Goel S, Harries AD, *et al.* Prevalence of extended treatment in pulmonary tuberculosis patients receiving first-line therapy and its association with recurrent tuberculosis in Beijing, China. *Trans R Soc Trop Med Hyg* 2014; **108**: 402–7.

170 Yan L, Kan X, Zhu L, *et al.* Short-course Regimen for Subsequent Treatment of Pulmonary Tuberculosis: A Prospective, Randomized, Controlled Multicenter Clinical Trial in China. *Clin Ther* 2018; **40**: 440–9.

171 Yen Y-F, Yen M-Y, Lin Y-S, *et al.* Smoking increases risk of recurrence after successful anti-tuberculosis treatment: a population-based study. *Int J Tuberc Lung Dis* 2014; **18**: 492–8.

172 Yoshiyama T, Morimoto K, Okumura M, *et al.* Long term outcome of multidrug-resistant TB patients in Fukujuji Hospital in Japan. *Trans R Soc Trop Med Hyg* 2014; **108**: 589–90.

173 Yoshiyama T, Shrestha B, Maharjan B. Risk of relapse and failure after retreatment with the Category II regimen in Nepal. *Int J Tuberc Lung Dis* 2010; **14**: 1418–23.

174 Zhdanov V, Bilenko N, Mor Z. Risk Factors for Recurrent Tuberculosis among Successfully Treated Patients in Israel, 1999 – 2011. *Isr Med Assoc J* 2017; **19**: 237-41

175 Zheng X-B, Diwan VK, Zhao Q, *et al.* Treatment quality and outcome for multidrug-resistant tuberculosis patients in four regions of China: a cohort study. *Infect Dis poverty* 2020;**9**:97. doi:10.1186/s40249-020-00719-x

176 Zierski M, Bek E, Long MW, Snider DEJ. Short-course (6-month) cooperative tuberculosis study in Poland: results 30 months after completion of treatment. *Am Rev Respir Dis* 1981; **124**: 249–51.